1
|
Radosevic-Robin N, Kossai M, Penault-Llorca F. New-generation technologies for spatial tissue analysis, indispensable tools for deciphering intratumor heterogeneity in the development of antibody-drug conjugates and radio-immunoconjugates for cancer treatment. Transl Breast Cancer Res 2023; 4:28. [PMID: 38751472 PMCID: PMC11093076 DOI: 10.21037/tbcr-23-38] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 09/12/2023] [Indexed: 05/18/2024]
Abstract
Technologies allowing in situ tissue molecular analysis of the "high-plex" type (>20 molecules per tissue section) are the 21st century inventions that are revolutionizing our knowledge of the biology of malignant tumors and many benign alterations. These technologies are based on specific probe labeling systems for the detection of tissue components [proteins, messenger RNA (mRNA)], as well as on detailed image analysis, combined with computational tools. We are synthetically presenting technologies based on image analysis, such as multiplex immunofluorescence (mIF), imaging mass cytometry (IMC), and multiplexed ion beam imaging (MIBI), as well as the ones not based on image analysis, such as multiplex in situ hybridizations (ISHs) using various principles. All of them are supported by powerful software which enable both tissue segmentation and data analysis. In the context of cancer treatment personalization, these technologies can reveal areas of tumor tissue and/or cellular subpopulations that are responsible for good or bad responses to anticancer drugs. Thus, they represent an unprecedented aid in the exploration of intratumor heterogeneity (ITH), which has already been shown to be one of the main reasons for the therapeutic failure of targeted anticancer treatments. The arrival of antibody-drug conjugates (ADCs) and radio-immunoconjugates (RICs) in the therapeutic arsenal in oncology imposes a deep exploration of molecular ITH, where technologies of spatial tissue analysis reveal an emerging category of biomarkers-spatial biomarkers.
Collapse
Affiliation(s)
- Nina Radosevic-Robin
- Platform for Advanced or/and Novel Tissue Analyses (TANYA), Department of Pathology, The Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France
- University Clermont Auvergne, INSERM U1240 [Molecular Imaging & Theragnostic Strategies (IMOST)], Clermont-Ferrand, France
| | - Myriam Kossai
- Platform for Advanced or/and Novel Tissue Analyses (TANYA), Department of Pathology, The Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France
- University Clermont Auvergne, INSERM U1240 [Molecular Imaging & Theragnostic Strategies (IMOST)], Clermont-Ferrand, France
| | - Frederique Penault-Llorca
- Platform for Advanced or/and Novel Tissue Analyses (TANYA), Department of Pathology, The Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France
- University Clermont Auvergne, INSERM U1240 [Molecular Imaging & Theragnostic Strategies (IMOST)], Clermont-Ferrand, France
| |
Collapse
|
2
|
Adam J, Stang NL, Uguen A, Badoual C, Chenard MP, Lantuéjoul S, Maran-Gonzalez A, Robin YM, Rochaix P, Sabourin JC, Soubeyran I, Sturm N, Svrcek M, Vincent-Salomon A, Radosevic-Robin N, Penault-Llorca F. Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions. Mod Pathol 2023; 36:100192. [PMID: 37084942 DOI: 10.1016/j.modpat.2023.100192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 03/14/2023] [Accepted: 04/12/2023] [Indexed: 04/23/2023]
Abstract
Pan-Trk immunohistochemistry has been described as a screening test for the detection of NTRK fusions in a broad spectrum of tumor types. However, pan-Trk testing in the clinical setting may be limited by many factors, including analytical parameters such as clones, platforms, and protocols used. This study aimed to harmonize pan-Trk testing using various clones and immunohistochemical (IHC) platforms and to evaluate the level of analytical variability across pathology laboratories. We developed several IHC pan-Trk assays using clones EPR17341 (Abcam) and A7H6R (Cell Signaling Technology) on Ventana/Roche, Agilent, and Leica platforms. To compare them, we sent unstained sections of a tissue microarray containing 9 cases with NTRK3 fusions to participating laboratories, to perform staining on Ventana/Roche (10 centers), Agilent (4 centers), and Leica (3 centers) platforms. A ready-to-use pan-Trk IVD assay (Ventana/Roche) was also performed in 3 centers. All slides were centrally and blindly reviewed for the percentage of stained tumor cells. Laboratory-developed tests with clone EPR17341 were able to detect pan-Trk protein expression in all cases, whereas lower rates of positivity were observed with clone A7H6R. Moderate to strong variability of the positive cases rate was observed with both antibodies in each IHC platforms type and each of the positivity cut points evaluated (≥1%, ≥10%, and ≥50% of stained tumor cells). The rate of false-negative cases was lower when pan-Trk staining was assessed with the lowest positivity threshold (≥1%). In conclusion, most evaluated pan-Trk IHC laboratory-developed tests were able to detect NTRK3-fusion proteins; however, a significant analytical variability was observed between antibodies, platforms, and centers.
Collapse
Affiliation(s)
- Julien Adam
- Pathology Department, Groupe Hospitalier Paris Saint-Joseph, Paris, and Inserm U1186, Gustave Roussy, Villejuif, France.
| | - Nolwenn Le Stang
- National Reference Center Mesopath, Centre Leon Berard, Lyon, France; Now with General Cancer Registry of Poitou-Charentes, Biology, Pharmacy and Public Health Unit, University Hospital, Poitiers, France
| | - Arnaud Uguen
- LBAI-UMR1227 - Inserm & Department of Pathology, CHU de Brest, Université de Brest, Brest, France
| | | | | | - Sylvie Lantuéjoul
- Université de Grenoble Alpes, Grenoble and Pathology Department, Centre Leon Berard, Lyon, France
| | | | | | | | | | | | | | - Magali Svrcek
- Pathology Department, Hôpital Saint-Antoine, AP-HP, Paris, France
| | | | - Nina Radosevic-Robin
- Pathology Department, Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240, Clermont-Ferrand, France
| | - Frédérique Penault-Llorca
- Pathology Department, Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240, Clermont-Ferrand, France
| |
Collapse
|
3
|
To NH, Gabelle-Flandin I, Luong TMH, Loganadane G, Ouidir N, Boukhobza C, Grellier N, Verry C, Thiolat A, Cohen JL, Radosevic-Robin N, Belkacemi Y. Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial. Cancers (Basel) 2023; 15:cancers15072030. [PMID: 37046691 PMCID: PMC10092968 DOI: 10.3390/cancers15072030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 03/22/2023] [Accepted: 03/28/2023] [Indexed: 03/31/2023] Open
Abstract
Background: Radiation therapy (RT), a novel approach to boost the anticancer immune response, has been progressively evaluated in the neoadjuvant setting in breast cancer (BC). Purpose: We aimed to evaluate immunity-related indicators of response to neoadjuvant chemoradiation therapy (NACRT) in BC for better treatment personalization. Patients and Methods: We analyzed data of the first 42 patients included in the randomized phase 2 Neo-APBI-01 trial comparing standard neoadjuvant chemotherapy (NACT) and NACRT regimen in locally advanced triple-negative (TN) and luminal B (LB) subtype BC. Clinicopathological parameters, blood counts and the derived parameters, total tumor-infiltrating lymphocytes (TILs) and their subpopulation, as well as TP53 mutation status, were assessed as predictors of response. Results: Twenty-one patients were equally assigned to each group. The pathologic complete response (pCR) was 33% and 38% in the NACT and NACRT groups, respectively, with a dose-response effect. Only one LB tumor reached pCR after NACRT. Numerous parameters associated with response were identified, which differed according to the assigned treatment. In the NACRT group, baseline hemoglobin of ≥13 g/dL and body mass index of <26 were strongly associated with pCR. Higher baseline neutrophils-to-lymphocytes ratio, total TILs, and T-effector cell counts were favorable for pCR. Conclusion: This preliminary analysis identified LB and low-TIL tumors as poor responders to the NACRT protocol, which delivered RT after several cycles of chemotherapy. These findings will allow for amending the selection of patients for the trial and help better design future trials of NACRT in BC.
Collapse
|
4
|
To NH, Kossai M, Ouidir N, Grellier N, Assaf E, Gabelle-Flandin I, Belkacemi Y, Radosevic-Robin N. Atypical responses to neoadjuvant chemotherapy combined with accelerated partial breast tumor-directed radiotherapy: two cases and considerations for future clinical trials. Rep Pract Oncol Radiother 2022; 27:1114-1118. [PMID: 36632297 PMCID: PMC9826652 DOI: 10.5603/rpor.a2022.0112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 10/04/2022] [Indexed: 12/12/2022] Open
Affiliation(s)
- Nhu Hanh To
- Department of Radiation Oncology and The Henri Mondor Breast Center, The Henri Mondor University Hospital, Creteil, France,University of Paris-Est Créteil (UPEC), Creteil, France,INSERM Unit 955, Immunoregulation and Biotherapy (I-Biot) Team, The Mondor Institute for Biomedical Research (IMRB), Creteil, France,Transatlantic Radiation Oncology Network (TRONE), Créteil, France
| | - Myriam Kossai
- Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France,University Clermont Auvergne, INSERM Unit 1240 (IMoST), Radiopharmaceuticals & Biomarkers (RoBust) Team, Clermont-Ferrand, France
| | - Nabila Ouidir
- Department of Pathology, The Henri Mondor University Hospital, AP-HP, Creteil, France
| | - Noemie Grellier
- Department of Radiation Oncology and The Henri Mondor Breast Center, The Henri Mondor University Hospital, Creteil, France
| | - Elias Assaf
- Department of Medical Oncology, The Henri Mondor University Hospital, Creteil, France
| | - Isabelle Gabelle-Flandin
- University Clinic of Cancerology-Radiotherapy, The Grenoble Alpes University Hospital Centre, La Tronche, France
| | - Yazid Belkacemi
- Department of Radiation Oncology and The Henri Mondor Breast Center, The Henri Mondor University Hospital, Creteil, France,University of Paris-Est Créteil (UPEC), Creteil, France,INSERM Unit 955, Immunoregulation and Biotherapy (I-Biot) Team, The Mondor Institute for Biomedical Research (IMRB), Creteil, France,Transatlantic Radiation Oncology Network (TRONE), Créteil, France,Association of Radiation Oncologists in the Mediterranean region (AROME), Creteil, France
| | - Nina Radosevic-Robin
- Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France,University Clermont Auvergne, INSERM Unit 1240 (IMoST), Radiopharmaceuticals & Biomarkers (RoBust) Team, Clermont-Ferrand, France,Association of Radiation Oncologists in the Mediterranean region (AROME), Creteil, France
| |
Collapse
|
5
|
Veyssière H, Aldarazi G, Molnar I, Durando X, Radosevic-Robin N. Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy. Anticancer Res 2022; 42:3583-3594. [PMID: 35790290 DOI: 10.21873/anticanres.15845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 05/05/2022] [Accepted: 06/01/2022] [Indexed: 11/10/2022]
Abstract
BACKGROUND High-grade epithelial ovarian cancer (HGEOC) is a heterogeneous disease and among the deadliest types of cancer. It often acquires resistance to conventional chemotherapy and its prognosis remains highly poor. The tissue protein nestin, implicated in the assembly and disassembly of intermediate filaments, has been reported to be an unfavourable prognostic factor in several cancer types. We hypothesized that HGEOC progression is regulated by the proliferation of chemoresistant cancer stem cells, in which nestin might be implicated. This preliminary study aimed to evaluate nestin as a prognostic biomarker in HGEOC treated by neoadjuvant chemotherapy (NACT) followed by cytoreductive surgery. PATIENTS AND METHODS A retrospective study (2009-2019) was conducted on 92 patients with primary ovarian, fallopian tube or peritoneal HGEOC who underwent NACT followed by cytoreductive surgery. Nestin expression in tissue samples was semi-quantitatively evaluated defining nestin positivity for those with histochemical score ≥30. We then evaluated the prognostic value of nestin expression. RESULTS The median progression-free survival was similar between nestin-positive (22 months) and nestin-negative (19 months) groups (p=0.57). Interestingly, the median overall survival was shorter for the nestin-positive group (48 vs. 67 months, respectively), however the difference did not reach statistical significance (p=0.43). CONCLUSION Tissue nestin expression does not appear to be a relevant prognostic biomarker in HGEOC treated by NACT. However, we believe that prospective studies in larger cohorts should be conducted and evaluation of nestin in pre-NACT HGEOC samples needs to be explored.
Collapse
Affiliation(s)
- Hugo Veyssière
- University of Clermont Auvergne, INSERM, U1240, Molecular Imaging and Theranostic Strategies, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France; .,Clinical Research Division, Clinical Research and Innovation Delegation, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France.,Clinical Investigation Center, UMR501, Clermont-Ferrand, France
| | - Ghassan Aldarazi
- Clinical Research Division, Clinical Research and Innovation Delegation, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France.,Clinical Investigation Center, UMR501, Clermont-Ferrand, France.,Department of Medical Oncology, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France
| | - Ioana Molnar
- University of Clermont Auvergne, INSERM, U1240, Molecular Imaging and Theranostic Strategies, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France.,Clinical Research Division, Clinical Research and Innovation Delegation, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France.,Clinical Investigation Center, UMR501, Clermont-Ferrand, France
| | - Xavier Durando
- University of Clermont Auvergne, INSERM, U1240, Molecular Imaging and Theranostic Strategies, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France.,Clinical Research Division, Clinical Research and Innovation Delegation, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France.,Clinical Investigation Center, UMR501, Clermont-Ferrand, France.,Department of Medical Oncology, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Department of Anatomy and Pathological Cytology, Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France
| |
Collapse
|
6
|
To NH, Radosevic-Robin N, Belkacemi Y. Neoadjuvant radiotherapy in triple-negative breast cancer: "the past should not steal the present or hide the future". Rep Pract Oncol Radiother 2022; 27:180-181. [PMID: 35402032 PMCID: PMC8989450 DOI: 10.5603/rpor.a2022.0127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 10/13/2021] [Indexed: 11/07/2022] Open
Affiliation(s)
- Nhu Hanh To
- AP-HP, Radiation Oncology Department and Henri Mondor Breast Center, Henri Mondor University Hospital, Créteil, France,INSERM Unit 955, Immunoregulation and Biotherapy (I-Biot) team, Mondor Institute of Biomedical Research (IMRB), Créteil, France
| | - Nina Radosevic-Robin
- Department of Pathology, Centre Jean Perrin, University Clermont Auvergne, INSERM U1240, Clermont-Ferrand, France
| | - Yazid Belkacemi
- AP-HP, Radiation Oncology Department and Henri Mondor Breast Center, Henri Mondor University Hospital, Créteil, France,University of Paris-Est Créteil (UPEC), Créteil, France,INSERM Unit 955, Immunoregulation and Biotherapy (I-Biot) team, Mondor Institute of Biomedical Research (IMRB), Créteil, France
| |
Collapse
|
7
|
To NH, Radosevic-Robin N, Belkacemi Y. Neoadjuvant radiotherapy in triple-negative breast cancer: “the past should not steal the present or hide the future”. Rep Pract Oncol Radiother 2022. [DOI: 10.5603/rpor.a2021.0127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Radosevic-Robin N, Lusho S, Durando X, Mouret-Reynier MA, Kossai M, Lacrampe N, Molnar I, Penault-Llorca F, Abrial C. Abstract P1-08-24: Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p1-08-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Triple negative breast cancer (TNBC) is highly heterogeneous, but still most of the patients are treated by the anthracycline/taxane-based neoadjuvant therapy (NACT). Tumor-infiltrating lymphocytes (TILs) are a strong predictive and prognostic biomarker in TNBC, however not always available due to organizational and analytical issues. Peripheral blood counts, which reflect the systemic inflammatory/immune status, are easier to obtain than TILs. We investigated whether baseline white cell or platelet counts, as well as Neutrophil-to-Lymphocyte Ratio (NLR) or Platelet-to-Lymphocyte Ratio (PLR) could replace baseline TILs as predictive or prognostic biomarkers in a series of TNBC treated by standard NACT. Patients and methods: One hundred twenty patients uniformly treated by FEC/taxane NACT in a tertiary cancer care center were retrospectively analyzed. The presence of pathological complete response (pCR: ypT0/Tis, ypN0) or the presence of pCR and small residual disease (ypT0/Tis/T1ab, ypN0) were considered as good responses in data analysis. Baseline/pre-NACT blood count, NLR, PLR and TILs were evaluated as predictors of response, distant recurrence rate and distant recurrence-free survival (DRFS). TILs were assessed on breast tumor biopsies according to the recommendations of the International Immuno-Oncology Biomarker Working Group (www.tilsinbreastcancer.org). Results: TILs ≥30% and ≥1.5% were best predictors of pCR and distant recurrence risk, respectively (p=0.007, p=0.012). However, in this cohort, pCR status was not significantly associated with recurrence. Only the ensemble of patients with pCR and small residual disease had lower recurrence risk and longer survival DRFS (p=0.042, p=0.024, respectively) than the rest of the cohort (larger residual disease). The only parameter which could predict the pCR/small residual disease status was PLR: patients with values lower than 133.25 had significantly higher chance of reaching that status after NACT (p=0.045). However, no direct correlation could be established between baseline PLR and metastatic recurrence. No correlation either was found between TIL and individual blood counts, or between TILs and NLR or PLR. Conclusion: In this cohort, TILs retained their pCR predictive value, however PLR was better predictor of the ensemble of responses which had good outcome in terms of less distant recurrences or longer DRFS (pCR or small residual disease). Thus, baseline PLR is worth further, prospective investigation together with baseline TILs, as it might indicate a good TNBC response to NACT when TILs are unavailable.
Citation Format: Nina Radosevic-Robin, Sejdi Lusho, Xavier Durando, Marie-Ange Mouret-Reynier, Myriam Kossai, Nathalie Lacrampe, Ioana Molnar, Frederique Penault-Llorca, Catherine Abrial. Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-24.
Collapse
Affiliation(s)
- Nina Radosevic-Robin
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Pathology, Clermont-Ferrand, France
| | - Sejdi Lusho
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Clinical Research, Clermont-Ferrand, France
| | - Xavier Durando
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Oncology, Department of Clinical Research, Clermont-Ferrand, France
| | - Marie-Ange Mouret-Reynier
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Oncology, Clermont-Ferrand, France
| | - Myriam Kossai
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Pathology, Clermont-Ferrand, France
| | - Nathalie Lacrampe
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Pathology, Clermont-Ferrand, France
| | - Ioana Molnar
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Clinical Research, Clermont-Ferrand, France
| | - Frederique Penault-Llorca
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Pathology, Clermont-Ferrand, France
| | - Catherine Abrial
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Clinical Research, Clermont-Ferrand, France
| |
Collapse
|
9
|
Khaled N, Sonnier N, Molnar I, Ponelle-Chachuat F, Kossai M, Radosevic-Robin N, Privat M, Bidet Y. RNA sequencing reveals the differential expression profiles of RNA in metastatic triple negative breast cancer and identifies SHISA3 as an efficient tumor suppressor gene. Am J Cancer Res 2021; 11:4568-4581. [PMID: 34659906 PMCID: PMC8493395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 05/26/2021] [Indexed: 06/13/2023] Open
Abstract
Breast cancer metastasis is the second leading cause of female mortality worldwide. Because of the heterogeneity within the group, metastatic biomarkers for triple-negative breast cancer (TNBC) providing predictive and prognosis values are urgently needed. Using RNA-Seq, we analyzed the transcriptome profiles of two groups of TNBCs tumors with or without distant metastasis. Whole transcriptome sequencing identified a set of genes implicated in TNBC metastasis with major roles in cell-cell adhesion, immune-modulation, and Wnt/β-catenin pathways. We further selected the SHISA3 gene and studied its biological significance through a series of in vitro and in vivo experiments. SHISA3 is a tumor suppressor gene, involved in several types of cancer. However, little is known concerning the role of SHISA3 in TNBC. Our in vitro and in vivo studies demonstrate that overexpression of SHISA3 inhibits TNBCs cell proliferation, metastasis and colony formation, and TNBC growth in xenografts. Mechanistically, SHISA3 inhibits TNBCs development and growth via downregulation of the epithelial-mesenchymal transition. Taken together, these results identified SHISA3 as a novel tumor suppressor gene in TNBC and suggest that SHISA3 could serve as a therapeutic target for TNBC patients.
Collapse
Affiliation(s)
- Noura Khaled
- Université Clermont Auvergne, InsermIMoST UMR 1240, F-63000 Clermont-Ferrand, France
- Centre Jean Perrin, Laboratoire d’Oncologie MoléculaireIMoST UMR 1240, F-63000 Clermont-Ferrand, France
| | - Nicolas Sonnier
- Centre Jean Perrin, Laboratoire d’Oncologie MoléculaireIMoST UMR 1240, F-63000 Clermont-Ferrand, France
| | - Ioana Molnar
- Université Clermont Auvergne, InsermIMoST UMR 1240, F-63000 Clermont-Ferrand, France
- Centre Jean Perrin, Laboratoire d’Oncologie MoléculaireIMoST UMR 1240, F-63000 Clermont-Ferrand, France
| | - Flora Ponelle-Chachuat
- Centre Jean Perrin, Laboratoire d’Oncologie MoléculaireIMoST UMR 1240, F-63000 Clermont-Ferrand, France
| | - Myriam Kossai
- Université Clermont Auvergne, InsermIMoST UMR 1240, F-63000 Clermont-Ferrand, France
- Centre Jean Perrin, Laboratoire d’Oncologie MoléculaireIMoST UMR 1240, F-63000 Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Université Clermont Auvergne, InsermIMoST UMR 1240, F-63000 Clermont-Ferrand, France
- Centre Jean Perrin, Laboratoire d’Oncologie MoléculaireIMoST UMR 1240, F-63000 Clermont-Ferrand, France
| | - Maud Privat
- Université Clermont Auvergne, InsermIMoST UMR 1240, F-63000 Clermont-Ferrand, France
- Centre Jean Perrin, Laboratoire d’Oncologie MoléculaireIMoST UMR 1240, F-63000 Clermont-Ferrand, France
| | - Yannick Bidet
- Université Clermont Auvergne, InsermIMoST UMR 1240, F-63000 Clermont-Ferrand, France
- Centre Jean Perrin, Laboratoire d’Oncologie MoléculaireIMoST UMR 1240, F-63000 Clermont-Ferrand, France
| |
Collapse
|
10
|
Kossai M, Radosevic-Robin N, Penault-Llorca F. Refining patient selection for breast cancer immunotherapy: beyond PD-L1. ESMO Open 2021; 6:100257. [PMID: 34487970 PMCID: PMC8426207 DOI: 10.1016/j.esmoop.2021.100257] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 07/27/2021] [Accepted: 08/03/2021] [Indexed: 02/07/2023] Open
Abstract
Therapies that modulate immune response to cancer, such as immune checkpoint inhibitors, began an intense development a few years ago; however, in breast cancer (BC), the results have been relatively disappointing so far. Finding biomarkers for better selection of BC patients for various immunotherapies remains a significant unmet medical need. At present, only tumour tissue programmed death-ligand 1 (PD-L1) and mismatch repair deficiency status are approved as theranostic biomarkers for programmed cell death-1 (PD-1)/PD-L1 inhibitors in BC. However, due to the complexity of tumour microenvironment (TME) and cancer response to immunomodulators, none of them is a perfect selector. Therefore, an intense quest is ongoing for complementary tumour- or host-related predictive biomarkers in breast immuno-oncology. Among the upcoming biomarkers, quantity, immunophenotype and spatial distribution of tumour-infiltrating lymphocytes and other TME cells as well as immune gene signatures emerge as most promising and are being increasingly tested in clinical trials. Biomarkers or strategies allowing dynamic assessment of BC response to immunotherapy, such as circulating/exosomal PD-L1, quantity of white/immune blood cell subpopulations and molecular imaging are particularly suitable for immunotreatment monitoring. Finally, host-related factors, such as microbiome and lifestyle, should also be taken into account when planning integration of immunomodulating therapies into BC management. As none of the biomarkers taken separately is accurate enough, the solution could come from composite biomarkers, which would combine clinical, molecular and immunological features of the disease, possibly powered by artificial intelligence. At present, immune checkpoint inhibitors (ICIs) are the only approved immunotherapy drugs in BC. Tumour PD-L1 and microsatellite status are current companion biomarkers for ICIs in BC; however, these need improvement. Evaluation of tumour immune contexture and the dynamics of circulating immune cell counts are promising novel approaches. Development of noninvasive monitoring and composite biomarkers will facilitate cancer immunotherapy, including in BC.
Collapse
Affiliation(s)
- M Kossai
- Department of Pathology, University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Clermont-Ferrand, France
| | - N Radosevic-Robin
- Department of Pathology, University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Clermont-Ferrand, France.
| | - F Penault-Llorca
- Department of Pathology, University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Clermont-Ferrand, France
| |
Collapse
|
11
|
Svrcek M, Colle R, Cayre A, Mas L, Bourgoin P, Cohen R, André T, Penault-Llorca F, Radosevic-Robin N. 444P Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Lusho S, Durando X, Mouret-Reynier MA, Kossai M, Lacrampe N, Molnar I, Penault-Llorca F, Radosevic-Robin N, Abrial C. Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients. Front Oncol 2021; 11:678315. [PMID: 34367964 PMCID: PMC8331686 DOI: 10.3389/fonc.2021.678315] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 06/29/2021] [Indexed: 12/31/2022] Open
Abstract
Introduction Triple negative breast cancer (TNBC) is highly heterogeneous, but still most of the patients are treated by the anthracycline/taxane-based neoadjuvant therapy (NACT). Tumor-infiltrating lymphocytes (TILs) are a strong predictive and prognostic biomarker in TNBC, however are not always available. Peripheral blood counts, which reflect the systemic inflammatory/immune status, are easier to obtain than TILs. We investigated whether baseline white cell or platelet counts, as well as, Neutrophil-to-Lymphocyte Ratio (NLR) or Platelet-to-Lymphocyte Ratio (PLR) could replace baseline TILs as predictive or prognostic biomarkers in a series of TNBC treated by standard NACT. Patients and Methods One hundred twenty patients uniformly treated by FEC/taxane NACT in a tertiary cancer care center were retrospectively analyzed. The presence of pathological complete response (pCR: ypT0/Tis, ypN0) or the presence of pCR and/small residual disease (ypT0/Tis/T1ab, ypN0) were considered as good responses in data analysis. Baseline/pre-NACT blood count, NLR, PLR and TILs were evaluated as predictors of response, distant recurrence rate and distant recurrence-free survival (DRFS). Results TILs ≥30% and ≥1.5% were best predictors of pCR and distant recurrence risk, respectively (p = 0.007, p = 0.012). However, in this cohort, pCR status was not significantly associated with recurrence. Only the ensemble of patients with pCR and small residual disease had lower recurrence risk and longer survival DRFS (p = 0.042, p = 0.024, respectively) than the rest of the cohort (larger residual disease). The only parameter which could predict the pCR/small residual disease status was PLR: patients with values lower than 133.25 had significantly higher chance of reaching that status after NACT (p = 0.045). However, no direct correlation could be established between baseline PLR and metastatic recurrence. No correlation either was found between TIL and individual blood counts, or between TILs and NLR or PLR. Conclusion In this cohort, TILs retained their pCR predictive value; however PLR was a better predictor of the ensemble of responses which had good outcome in terms of less distant recurrences or longer DRFS (pCR or small residual disease). Thus, baseline PLR is worth further, prospective investigation together with baseline TILs, as it might indicate a good TNBC response to NACT when TILs are unavailable.
Collapse
Affiliation(s)
- Sejdi Lusho
- Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.,Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.,Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France
| | - Xavier Durando
- Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.,Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.,Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France.,Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France
| | - Marie-Ange Mouret-Reynier
- Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.,Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.,Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France.,Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France
| | - Myriam Kossai
- Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.,Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France
| | - Nathalie Lacrampe
- Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.,Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France
| | - Ioana Molnar
- Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.,Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.,Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France
| | - Frederique Penault-Llorca
- Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.,Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France
| | - Catherine Abrial
- Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.,Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.,Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France
| |
Collapse
|
13
|
Cheradame L, Guerrera IC, Gaston J, Schmitt A, Jung V, Pouillard M, Radosevic-Robin N, Modesti M, Judde JG, Goffin V, Cairo S. Abstract 2038: A non-canonical, cell-autonomous STING function protects breast cancer cells from intrinsic and genotoxic-induced DNA instability. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-2038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Several studies have recently indicated the activation of the immune system against tumor cells as well as the targeting of cancer cell DNA damage repair mechanisms as effective strategies to target tumor growth. STING is a well-known DNA sensor of innate immunity mostly characterized as a transmembrane protein of various cytoplasmic organelles that senses cytosolic DNA as a danger signal and triggers inflammatory responses. A current cancer immunotherapy strategy relies on the use of STING agonists to boost the patient's immune system through a cytokine-mediated recruitment of immune cells that infiltrate and kill tumor cells. However, the role of the STING pathway in cancer is far to be fully understood as there is otherwise accumulating evidence that activation of the cGAS-STING pathway can have a deleterious outcome. We recently showed that genotoxic treatment of breast cancer PDXs and cell lines triggered the STING pathway. Genetic inhibition of this pathway in MCF7 cells increased genotoxic treatment efficacy by promoting cell death and delaying cell colony regrowth, indicating that STING pathway intrinsically promotes cell resistance to treatment. In this study, we show that STING silencing decreased cell viability in a panel of classical or PDX-derived breast cancer cell lines irrespective of their ER status and of the genotoxic treatment received. Cell fractionation indicates that part of the STING pool intrinsically resides in the nucleus of various malignant and non-malignant cells. Fluorescence and electron microscopy show that STING partly resides at the inner membrane of the nucleus, and mass-spectrometry analysis revealed that STING interacts with core proteins of the non-homologous end joining (NHEJ) DNA damage repair (DDR) complex. STING promotes NEHJ-related protein assembly with chromatin, and its silencing decreases DDR and cell viability, while STING overexpression protects cancer cells from genotoxic treatment. STING involvement in DDR is independent of the classical STING-TBK1-IFN inflammatory response, thus identifying a new functional pathway for STING. STING nuclear localization was confirmed in a panel of breast cancer patient-derived xenografts and in surgical samples from breast cancer patients that received neoadjuvant chemotherapy. Evaluation of the impact of STING expression on patient outcome via the Kaplan Meier plotter show that overall STING expression level is positively correlated with favorable outcome in breast cancer patients, however high STING expression in breast and ovarian cancer patients treated with adjuvant chemotherapy is associated with poor prognosis. These findings place STING at the crossroad of DDR and immune surveillance, two major pathways for tumorigenesis and tumor survival.
Citation Format: Laura Cheradame, Ida Chiara Guerrera, Julie Gaston, Alain Schmitt, Vincent Jung, Marion Pouillard, Nina Radosevic-Robin, Mauro Modesti, Jean-Gabriel Judde, Vincent Goffin, Stefano Cairo. A non-canonical, cell-autonomous STING function protects breast cancer cells from intrinsic and genotoxic-induced DNA instability [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2038.
Collapse
Affiliation(s)
| | - Ida Chiara Guerrera
- 2Proteomics Platform 3P5-Necker, Université Paris Descartes - Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Paris, France
| | | | - Alain Schmitt
- 3Inserm U1016 and CNRS UMR8104, Paris Descartes University, Paris, France
| | - Vincent Jung
- 2Proteomics Platform 3P5-Necker, Université Paris Descartes - Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Paris, France
| | - Marion Pouillard
- 4Université de Paris, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades, Paris, France
| | - Nina Radosevic-Robin
- 5U1240 INSERM/University Clermont Auvergne, Centre Jean Perrin, Clermont Ferrand, France
| | - Mauro Modesti
- 3Inserm U1016 and CNRS UMR8104, Paris Descartes University, Paris, France
| | | | - Vincent Goffin
- 4Université de Paris, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades, Paris, France
| | | |
Collapse
|
14
|
Veyssière H, Lusho S, Molnar I, Kossai M, Bernadach M, Abrial C, Bidet Y, Radosevic-Robin N, Durando X. INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer. Front Oncol 2021; 11:653370. [PMID: 34249690 PMCID: PMC8268015 DOI: 10.3389/fonc.2021.653370] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Accepted: 06/09/2021] [Indexed: 12/31/2022] Open
Abstract
Background Triple negative breast cancer (TNBC) accounts for 10-20% of breast cancers but has no specific therapy. While TNBC may be more sensitive to chemotherapy than other types of breast cancer, it has a poor prognosis. Most TNBC relapses occur during the five years following treatment, however predictive biomarkers of metastatic relapse are still lacking. High tumour-infiltrating lymphocytes (TILs) levels before and after neo-adjuvant chemotherapy (NAC) are associated with lower relapse risk and longer survival but TILs assessment is highly error-prone and still not introduced into the clinic. Therefore, having reliable biomarker of relapse, but easier to assess, remains essential for TNBC management. Searching for such biomarkers among serum/plasma proteins, circulating tumoral DNA (ctDNA) and blood cells appear relevant. Methods This single-centre and prospective study aims to discover predictive biomarkers of TNBC relapse and particularly focuses on plasma proteins. Blood samples will be taken at diagnosis, on the day of first-line or post-NAC surgery, on the day of radiotherapy start, then 6 months and one year after radiotherapy. A blood sample will be taken at the time of metastatic relapse diagnosis. Blood samples will be used for circulating protein quantification, blood cell counts and circulating tumour DNA quantification. A tumour RNA signature, based on the analysis of the RNA expression of 6 genes, will also be tested from the initial biopsy taken routinely. In NAC patients, TILs quantity will be assessed on TNBC pre-treatment biopsy and surgical specimen. Ethics and Dissemination INSTIGO belongs to category 2 interventional research on humans. This study has been approved by the SUD-EST IV ethics committee and is conducted in accordance with the Declaration of Helsinki and General Data Protection Regulation (GDPR). Study findings will be published in peer-reviewed medical journals. Clinical Trial Registration ClinicalTrials.gov, identifier NCT04438681.
Collapse
Affiliation(s)
- Hugo Veyssière
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean PERRIN, Clermont-Ferrand, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean PERRIN, Clermont-Ferrand, France.,Centre d'Investigation Clinique, UMR501, Clermont-Ferrand, France
| | - Sejdi Lusho
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean PERRIN, Clermont-Ferrand, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean PERRIN, Clermont-Ferrand, France.,Centre d'Investigation Clinique, UMR501, Clermont-Ferrand, France
| | - Ioana Molnar
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean PERRIN, Clermont-Ferrand, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean PERRIN, Clermont-Ferrand, France.,Centre d'Investigation Clinique, UMR501, Clermont-Ferrand, France
| | - Myriam Kossai
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean PERRIN, Clermont-Ferrand, France.,Département d'anatomie et de cytologie pathologiques, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Maureen Bernadach
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean PERRIN, Clermont-Ferrand, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Catherine Abrial
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean PERRIN, Clermont-Ferrand, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean PERRIN, Clermont-Ferrand, France.,Centre d'Investigation Clinique, UMR501, Clermont-Ferrand, France
| | - Yannick Bidet
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean PERRIN, Clermont-Ferrand, France.,Département d'oncogénétique, Laboratoire d'Oncologie Moléculaire, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean PERRIN, Clermont-Ferrand, France.,Département d'anatomie et de cytologie pathologiques, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Xavier Durando
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean PERRIN, Clermont-Ferrand, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean PERRIN, Clermont-Ferrand, France.,Centre d'Investigation Clinique, UMR501, Clermont-Ferrand, France
| |
Collapse
|
15
|
Svrcek M, Colle R, Cayre A, Bourgoin P, Cohen R, Andre T, Penault-Llorca FM, Radosevic-Robin N. Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e15537] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15537 Background: Inhibitors of tropomyosin receptor kinase (TRK) have shown promising activity against neurotrophic TRK ( NTRK) fusion-driven cancers, regardless of tumor histotype or cell of origin. NTRK gene fusions are observed in less than 1% of colorectal cancers (CRCs). CRCs harboring wild-type BRAF and KRAS and MisMatch Repair deficiency (dMMR)/MicroSatellite Instability (MSI) due to MLH1 hypermethylation have been associated with NTRK fusions in small cohorts of non-metastatic tumors. We aimed at evaluating the incidence of NTRK fusions among dMMR/MSI metastatic CRCs (mCRC) for which there is a need for innovative therapies, as well as the associated clinical characteristics of these patients (pts) carrying NTRK fusion-positive tumors. Methods: Tumor samples of dMMR/MSI mCRC pts, paired primary and metastasis or primary alone, were obtained from a French multicenter retrospective cohort and from a single-center cohort of patients treated by immune checkpoint inhibitors (ICI) (Saint-Antoine Hospital, Paris). Clinico-pathological data including KRAS and BRAFV600E status, MMR proteins and MLH1 methylation status were available for all pts. All samples were screened for TRK expression by immunohistochemistry (IHC) using a pan-TRK antibody (clone EPR17341, Abcam; positivity: 1% of labeled tumor cells)) and for NTRK1 and NTRK3 gene rearrangements, by fluorescent in situ hybridation (FISH). A threshold of 15% nuclei positive for a break apart signal was considered positive for gene rearrangement. Results: A total of 158 pts with dMMR/MSI mCRCs (paired samples: n=39; primary only: n=119) were screened. Tumor samples of 10 patients (6.3%) harbored NTRK fusion genes by FISH ( NTRK1=8; NTRK3=2). Only four of these 10 patients had TRK immunoreactivity. One patient showed a discordance between metastasis harboring NTRK1 fusion (+) and primary tumor being negative. Eight tumors were sporadic with MLH1 hypermethylation. The remaining 2 cases were related to a MMR gene germline mutation (Lynch syndrome) with concurrent loss of MSH2 and MSH6 expression and isolated loss of MSH6 respectively. One Lynch-related tumor was KRAS mutated, one sporadic MLH1-negative tumor was BRAF V600E mutated. Four patients out of 91 treated by ICI had tumors with NTRK fusions. Three have shown radiological response according to iRECIST criteria (two complete responses, one partial response with 25 to 54 months of follow up) and one had primary resistance to ICI. Conclusions: Frequency of NTRK1/3 fusions is 6.3% in our dMMR/MSI mCRCs population. These fusions are not restricted to sporadic cases. The diagnostic accuracy of pan-TRK IHC is low. Optimal testing algorithms for theragnostics remain to be defined in this setting.
Collapse
Affiliation(s)
- Magali Svrcek
- Inserm Umrs_938, Team “Microsatellite Instability and Cancer”, Siric Curamus, Paris, France
| | - Raphael Colle
- Assistance Publique Hôpitaux de Paris, Paris, France
| | - Anne Cayre
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Pathology, Clermont-Ferrand, France
| | - Pierre Bourgoin
- Sorbonne Université, INSERM UMRS_938, Microsatellite instability and cancer, SIRIC CURAMUS, Paris, France
| | | | - Thierry Andre
- Sorbonne Université, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France
| | | | - Nina Radosevic-Robin
- University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Pathology, Clermont-Ferrand, France
| |
Collapse
|
16
|
Delorme S, Privat M, Sonnier N, Rouanet J, Witkowski T, Kossai M, Mishellany F, Radosevic-Robin N, Juban G, Molnar I, Quintana M, Degoul F. New insight into the role of ANXA1 in melanoma progression: involvement of stromal expression in dissemination. Am J Cancer Res 2021; 11:1600-1615. [PMID: 33948376 PMCID: PMC8085877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Accepted: 12/28/2020] [Indexed: 06/12/2023] Open
Abstract
ANXA1, first described in the context of inflammation, appears to be deregulated in many cancers and increased in melanomas compared with melanocytes. To date, few studies have investigated the role of ANXA1 in melanoma progression. Furthermore, this protein is expressed by various cell types, including immune and endothelial cells. We therefore analyzed the specific roles of ANXA1 using melanoma and stromal cells in two human cell lines (A375-MA2 and SK-MEL-28) in vitro and in Anxa1 null C57Bl6/J mice bearing B16Bl6 tumors. We report decreased proliferation in both ANXA1 siRNA A375-MA2 and SK-MEL-28, but cell-dependent effects of ANXA1 in migration in vitro. However, we also observed a significant decrease of B16Bl6 tumor growth associated with a reduction of Ki-67 positive cells in Anxa1 null mice compared with wild-type mice. Interestingly, we also found a significant reduction of spontaneous metastases, which can be attributed to decreased angiogenesis concomitantly with greater immune cell presence in the Anxa1 null stromal context. This study highlights the pejorative role of ANXA1 in both tumor and stromal cells in melanoma, due to its involvement in proliferation and angiogenesis.
Collapse
Affiliation(s)
- Solène Delorme
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| | - Maud Privat
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département d’Oncogénétique, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Nicolas Sonnier
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département d’Oncogénétique, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Jacques Rouanet
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| | - Tiffany Witkowski
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| | - Myriam Kossai
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département de Pathologie, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Florence Mishellany
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département de Pathologie, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Nina Radosevic-Robin
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département de Pathologie, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Gaëtan Juban
- Institut NeuroMyoGène, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U1217, Université LyonLyon 69008, France
| | - Ioana Molnar
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département de Recherche Clinique et Innovation, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Mercedes Quintana
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| | - Françoise Degoul
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| |
Collapse
|
17
|
Gataa I, Mezquita L, Rossoni C, Auclin E, Kossai M, Aboubakar F, Le Moulec S, Massé J, Masson M, Radosevic-Robin N, Alemany P, Rouanne M, Bluthgen V, Hendriks L, Caramella C, Gazzah A, Planchard D, Pignon JP, Besse B, Adam J. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. Eur J Cancer 2021; 145:221-229. [PMID: 33516050 DOI: 10.1016/j.ejca.2020.10.017] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Revised: 10/01/2020] [Accepted: 10/08/2020] [Indexed: 10/22/2022]
Abstract
BACKGROUND The established role of morphological evaluation of tumour-infiltrating lymphocytes (TILs) with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) is unknown. We aimed to determine TIL association with the outcome for ICIs and for chemotherapy in advanced NSCLC. METHODS This is a multicenter retrospective study of a nivolumab cohort of 221 patients treated between November 2012 and February 2017 and a chemotherapy cohort of 189 patients treated between June 2009 and October 2016. Patients with available tissue for stromal TIL evaluation were analysed. The presence of a high TIL count (high-TIL) was defined as ≥10% density. The primary end-point was overall survival (OS). RESULTS Among the nivolumab cohort, 64% were male, with median age of 63 years, 82.3% were smokers, 77% had performance status ≤1 and 63% had adenocarcinoma histology. High-TIL was observed in 22% patients and associated with OS (hazard ratio [HR] 0.48; 95% confidence interval [95% CI]: 0.28-0.81) and progression-free survival [PFS] (HR = 0.40; 95% CI: 0.25-0.64). Median PFS was 13.0 months (95% CI: 5.0-not reached) with high-TIL versus 2.2 months (95% CI: 1.7-3.0) with the presence of a low TIL count (low-TIL). Median OS for high-TIL was not reached (95% CI: 12.2-not reached) versus 8.4 months (95% CI: 5.0-11.6) in the low-TIL group. High-TIL was associated with the overall response rate (ORR) and disease control rate (DCR) (both, P < .0001). Among the chemotherapy cohort, 69% were male, 89% were smokers, 86% had performance status ≤1 and 90% had adenocarcinoma histology. High-TIL was seen in 37%. Median PFS and OS were 5.7 months (95% CI: 4.9-6.7) and 11.7 months (95% CI: 9.3-13.0), respectively, with no association with TILs. CONCLUSIONS High-TIL was associated with favourable outcomes in a real-world immunotherapy cohort of patients with NSCLC, but not with chemotherapy, suggesting that TILs may be useful in selecting patients for immunotherapy.
Collapse
Affiliation(s)
- Ithar Gataa
- Cancer Medicine Department, Gustave Roussy, Villejuif, France; Medical Oncology Department, Cochin Hospital, Paris, France.
| | - Laura Mezquita
- Cancer Medicine Department, Gustave Roussy, Villejuif, France; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain.
| | - Caroline Rossoni
- Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Oncostat, U1018, Villejuif, France.
| | - Edouard Auclin
- Medical and Thoracic Oncology Department, Hôpital Européen Georges Pompidou AP-HP, Paris, France.
| | - Myriam Kossai
- Pathology Department, Gustave Roussy, Villejuif, France.
| | - Frank Aboubakar
- Cancer Medicine Department, Gustave Roussy, Villejuif, France.
| | | | - Julie Massé
- Pathology Department, Institut Bergonié, Bordeaux, France.
| | - Morgane Masson
- Medical Oncology Department, Centre Jean Perrin, Clermont-Ferrand, France.
| | | | - Pierre Alemany
- Pathology Department, Gustave Roussy, Villejuif, France.
| | - Mathieu Rouanne
- INSERM U1015, Gustave Roussy, Villejuif, France; Hôpital Foch, UVSQ-Université Paris-Saclay, Suresnes, France.
| | | | - Lizza Hendriks
- Cancer Medicine Department, Gustave Roussy, Villejuif, France; Department of Pulmonary Diseases, GROW - School for Oncology and Developmental Biology, Maastricht UMC+, Maastricht, the Netherlands.
| | | | - Anas Gazzah
- Early Drug Development Department, Gustave Roussy, Villejuif, France.
| | - David Planchard
- Cancer Medicine Department, Gustave Roussy, Villejuif, France.
| | - Jean-Pierre Pignon
- Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Oncostat, U1018, Villejuif, France.
| | - Benjamin Besse
- Cancer Medicine Department, Gustave Roussy, Villejuif, France; Paris-Saclay University, Faculty of Medicine, Le Kremlin, Bicêtre, France.
| | - Julien Adam
- Pathology Department, Gustave Roussy, Villejuif, France.
| |
Collapse
|
18
|
Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, Rubio IT, de Azambuja E, Curigliano G, Gentilini O, Gnant M, Günthert A, Hauser N, Heil J, Knauer M, Knotek-Roggenbauerc M, Knox S, Kovacs T, Kuerer HM, Loibl S, Mannhart M, Meattini I, Penault-Llorca F, Radosevic-Robin N, Sager P, Španić T, Steyerova P, Tausch C, Peeters MJTFDV, Weber WP, Cardoso MJ, Poortmans P. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncol 2021; 22:e18-e28. [PMID: 33387500 DOI: 10.1016/s1470-2045(20)30580-5] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Revised: 08/26/2020] [Accepted: 09/07/2020] [Indexed: 12/13/2022]
Abstract
Primary systemic therapy is increasingly used in the treatment of patients with early-stage breast cancer, but few guidelines specifically address optimal locoregional therapies. Therefore, we established an international consortium to discuss clinical evidence and to provide expert advice on technical management of patients with early-stage breast cancer. The steering committee prepared six working packages to address all major clinical questions from diagnosis to surgery. During a consensus meeting that included members from European scientific oncology societies, clinical trial groups, and patient advocates, statements were discussed and voted on. A consensus was reached in 42% of statements, a majority in 38%, and no decision in 21%. Based on these findings, the panel developed clinical guidance recommendations and a toolbox to overcome many clinical and technical requirements associated with the diagnosis, response assessment, surgical planning, and surgery of patients with early-stage breast cancer. This guidance could convince clinicians and patients of the major clinical advancements purported by primary systemic therapy, the use of less extensive and more targeted surgery to improve the lives of patients with breast cancer.
Collapse
Affiliation(s)
- Peter Dubsky
- Breast Centre, Hirslanden Klinik St Anna, Luzern, Switzerland; Department of Surgery, Medical University of Vienna, Vienna, Austria; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
| | - Katja Pinker
- Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria; Breast Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Fatima Cardoso
- Breast Unit, Champalimaud Clinical Center and Foundation, Lisbon, Portugal
| | - Giacomo Montagna
- Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Breast Center, University Hospital Basel, Basel, Switzerland
| | - Mathilde Ritter
- Breast Center, University Hospital Basel, Basel, Switzerland
| | - Carsten Denkert
- Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany
| | - Isabel T Rubio
- Breast Surgical Oncology Unit, Clinica Universidad de Navarra, Universidad de Navarra, Madrid, Spain
| | - Evandro de Azambuja
- Institut Jules Bordet, Brussels, Belgium; l'Université Libre de Bruxelles, Brussels, Belgium
| | | | - Oreste Gentilini
- Breast Surgery, San Raffaele University and Research Hospital, Milan, Italy
| | - Michael Gnant
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Andreas Günthert
- Breast Centre, Hirslanden Klinik St Anna, Luzern, Switzerland; Department of Breast Surgery, Gyn-zentrum Luzern, Luzern, Switzerland
| | - Nik Hauser
- Breast Centre Aarau Cham Zug, Hirslanden Klinik, Aarau, Switzerland; Frauenarztzentrum Aargau Ag, Baden, Switzerland
| | - Joerg Heil
- Heidelberg University Hospital, Heidelberg, Germany
| | - Michael Knauer
- Breast Center Eastern Switzerland, St Gallen, Switzerland
| | | | - Susan Knox
- Europa Donna-The European Breast Cancer Coalition, Milan, Italy
| | - Tibor Kovacs
- Department of Breast Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK; Breast Institute, Jiahui International Hospital, Shanghai, China
| | - Henry M Kuerer
- Division of Surgery, Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sibylle Loibl
- German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany
| | - Meinrad Mannhart
- Breast Centre Aarau Cham Zug, Hirslanden Klinik, Aarau, Switzerland
| | - Icro Meattini
- Department of Experimental and Clinical Biomedical Sciences "M Serio", University of Florence, Florence, Italy; Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - Frederique Penault-Llorca
- Department of Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, University Clermont Auvergne, INSERM U1240 IMoST, Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Department of Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, University Clermont Auvergne, INSERM U1240 IMoST, Clermont-Ferrand, France
| | | | - Tanja Španić
- Europa Donna-The European Breast Cancer Coalition, Milan, Italy
| | - Petra Steyerova
- Breast Cancer Screening and Diagnostic Center, Clinic of Radiology, General University Hospital in Prague, Prague, Czech Republic
| | | | | | - Walter P Weber
- Breast Center, University Hospital Basel, Basel, Switzerland; Faculty of Medicine, University of Basel, Basel, Switzerland
| | - Maria J Cardoso
- Breast Unit, Champalimaud Clinical Center and Foundation, Lisbon, Portugal; Nova Medical School, Lisbon, Portugal
| | - Philip Poortmans
- Iridium Kankernetwerk, Wilrijk-Antwerp, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk-Antwerp, Belgium
| |
Collapse
|
19
|
Rabia E, Garambois V, Hubert J, Bruciamacchie M, Pirot N, Delpech H, Broyon M, Theillet C, Colombo PE, Vie N, Tosi D, Gongora C, Khellaf L, Jarlier M, Radosevic-Robin N, Chardès T, Pèlegrin A, Larbouret C. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. MAbs 2021; 13:1914883. [PMID: 33876707 PMCID: PMC8078530 DOI: 10.1080/19420862.2021.1914883] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 03/30/2021] [Accepted: 04/06/2021] [Indexed: 01/02/2023] Open
Abstract
Chemoresistance, particularly to gemcitabine, is a major challenge in pancreatic cancer. The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptors 2 and 3 (HER2, HER3) are expressed in many tumors, and they are relevant therapeutic targets due to their synergistic interaction to promote tumor aggressiveness and therapeutic resistance. Cocktails of antibodies directed against different targets are a promising strategy to overcome these processes. Here, we found by immunohistochemistry that these three receptors were co-expressed in 11% of patients with pancreatic adenocarcinoma. We then developed gemcitabine-resistant pancreatic cancer cell models (SW-1990-GR and BxPC3-GR) and one patient-derived xenograft (PDX2846-GR) by successive exposure to increasing doses of gemcitabine. We showed that expression of EGFR, HER2 and HER3 was increased in these gemcitabine-resistant pancreatic cancer models, and that an antibody mixture against all three receptors inhibited tumor growth in mice and downregulated HER receptors. Finally, we demonstrated that the Pan-HER and gemcitabine combination has an additive effect in vitro and in mice xenografted with the gemcitabine-sensitive or resistant pancreatic models. The mixture of anti-EGFR, HER2 and HER3 antibodies is a good candidate therapeutic approach for gemcitabine-sensitive and -resistant pancreatic cancer.
Collapse
MESH Headings
- Animals
- Antibodies/pharmacology
- Antimetabolites, Antineoplastic/pharmacology
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Deoxycytidine/analogs & derivatives
- Deoxycytidine/pharmacology
- Drug Resistance, Neoplasm
- ErbB Receptors/antagonists & inhibitors
- ErbB Receptors/immunology
- ErbB Receptors/metabolism
- Female
- Humans
- Mice, Nude
- Pancreatic Neoplasms/drug therapy
- Pancreatic Neoplasms/immunology
- Pancreatic Neoplasms/metabolism
- Pancreatic Neoplasms/pathology
- Receptor, ErbB-2/antagonists & inhibitors
- Receptor, ErbB-2/immunology
- Receptor, ErbB-2/metabolism
- Receptor, ErbB-3/antagonists & inhibitors
- Receptor, ErbB-3/immunology
- Receptor, ErbB-3/metabolism
- Tumor Burden/drug effects
- Xenograft Model Antitumor Assays
- Gemcitabine
- Mice
Collapse
Affiliation(s)
- Emilia Rabia
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Véronique Garambois
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Julie Hubert
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Marine Bruciamacchie
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Nelly Pirot
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
- BioCampus Montpellier, Université Montpellier, CNRS UAR3426, INSERM US09, Université De Montpellier, Montpellier, France
| | - Hélène Delpech
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Morgane Broyon
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
- BioCampus Montpellier, Université Montpellier, CNRS UAR3426, INSERM US09, Université De Montpellier, Montpellier, France
| | - Charles Theillet
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | | | - Nadia Vie
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Diego Tosi
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
- Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Celine Gongora
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Lakhdar Khellaf
- Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Marta Jarlier
- Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Nina Radosevic-Robin
- Centre Jean Perrin, Université Clermont Auvergne, INSERM U1240, Clermont-Ferrand, France
| | - Thierry Chardès
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - André Pèlegrin
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| | - Christel Larbouret
- Institut De Recherche En Cancérologie De Montpellier (IRCM), INSERM U1194, Université De Montpellier, Institut Régional Du Cancer De Montpellier (ICM), Montpellier, France
| |
Collapse
|
20
|
Lusho S, Durando X, Bidet Y, Molnar I, Kossai M, Bernadach M, Lacrampe N, Veyssiere H, Cavaille M, Gay-Bellile M, Radosevic-Robin N, Abrial C. PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer. Medicine (Baltimore) 2020; 99:e23418. [PMID: 33327268 PMCID: PMC7738079 DOI: 10.1097/md.0000000000023418] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Triple negative breast cancer affects 10% to 20% of all women diagnosed with breast cancer. Due to its characteristics, treatment strategies are limited and metastatic recurrences are common in the first 5 years after treatment. However, not all patients affected by this disease develop metastases. Tumor-infiltrating lymphocytes have shown to be reliable predictive biomarkers of treatment response and metastatic recurrences. However, we need to develop simpler and faster ways to predict response to cytotoxic treatment and the possibility of eventual cancer relapse by identifying new biomarkers. Recently, new studies are emerging, suggesting a predictive role of circulating blood cells in different types of cancer. In this study, we will assess the correlation between tumor-infiltrating lymphocytes and different elements of the blood count in patients diagnosed with triple negative breast cancer. METHODS The main objective of this study is to evaluate the correlation between the peripheral neutrophil-to-lymphocyte ratio and the amount of tumor-infiltrating lymphocytes, assessed in triple negative breast cancer patients at diagnosis. Secondary objectives include evaluation of the correlation between tumor-infiltrating lymphocytes at diagnosis and the baseline absolute neutrophil, lymphocyte, and platelet counts, as well as the platelet-to-lymphocyte ratio. The triple negative breast cancer patients will be enrolled in the PERCEPTION trial during the first year after the treatment completion. Two supplementary blood tests, at 12 months after the end of treatment and at the time of the first metastatic recurrence, will be performed. DISCUSSION The discovery of new prognostic and predictive biomarkers is crucial for triple negative breast cancer. We set up the PERCEPTION clinical trial in order to evaluate certain blood counts as early biomarkers and to assess their correlation with tumor-infiltrating lymphocytes. Demonstration of comparative predictive and/or prognostic capacities of peripheral blood counts and tumor-infiltrating lymphocytes would allow introduction of the former as simple and cheap biomarkers in triple negative breast cancer patient management. TRIAL REGISTRATION The PERCEPTION study has been registered in the French National Agency of Medical Security registry on the 2nd of July 2019 under the number 2019-A01861-56 and in the ClinicalTrials.org registry under the number NCT04068623.
Collapse
Affiliation(s)
- Sejdi Lusho
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Délégation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand
- Centre d’Investigation Clinique, UMR501, F-63001 Clermont-Ferrand
| | - Xavier Durando
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Délégation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand
- Centre d’Investigation Clinique, UMR501, F-63001 Clermont-Ferrand
| | - Yannick Bidet
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Centre Jean PERRIN, Laboratoire d’oncologie moléculaire
| | - Ioana Molnar
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Délégation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand
- Centre d’Investigation Clinique, UMR501, F-63001 Clermont-Ferrand
| | - Myriam Kossai
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Centre Jean Perrin, Département d’anatomie et de cytologie pathologiques
| | - Maureen Bernadach
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Délégation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand
| | - Nathalie Lacrampe
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Centre Jean Perrin, Département d’anatomie et de cytologie pathologiques
| | - Hugo Veyssiere
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Délégation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand
- Centre d’Investigation Clinique, UMR501, F-63001 Clermont-Ferrand
| | - Mathias Cavaille
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Centre Jean Perrin, Département d’oncogénétique, 58 rue Montalembert, 63011 Clermont-Ferrand, France
| | - Mathilde Gay-Bellile
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Centre Jean Perrin, Département d’oncogénétique, 58 rue Montalembert, 63011 Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Centre Jean Perrin, Département d’anatomie et de cytologie pathologiques
| | - Catherine Abrial
- Université Clermont Auvergne, INSERM UMR 1240 «Imagerie Moléculaire et Stratégies Théranostiques», Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand
- Délégation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand
- Centre d’Investigation Clinique, UMR501, F-63001 Clermont-Ferrand
| |
Collapse
|
21
|
Veyssière H, Passildas J, Ginzac A, Lusho S, Bidet Y, Molnar I, Bernadach M, Cavaille M, Radosevic-Robin N, Durando X. XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Res 2020; 9:1219. [PMID: 34249349 PMCID: PMC8258709 DOI: 10.12688/f1000research.26873.3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/15/2021] [Indexed: 12/31/2022] Open
Abstract
Introduction: Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could be useful to better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made from metastatic tumours. Thus, PDX from primary mammary tumours or after neoadjuvant treatment are still rare. This study aims to assess the feasibility to establish xenografts from tumour samples of patients with triple negative or luminal B breast cancer in neoadjuvant, adjuvant or metastatic setting. Methods: XENOBREAST is a single-centre and prospective study. This feasibility pilot trial aims to produce xenografts from tumour samples of patients with triple negative or luminal B breast cancer. Patient enrolment is expected to take 3 years: 85 patients will be enrolled and followed for 28 months. Additional blood samples will be taken as part of the study. Surgical specimens from post-NAC surgery, primary surgery or surgical excision of the metastases will be collected to establish PDX. Histomolecular characteristics of the established PDX will be investigated and compared with the initial histomolecular profile of the collected tumours to ensure that they are well-established. Ethics and dissemination: XENOBREAST belongs to category 2 interventional research on the human person. This study has been approved by the Sud Méditerranée IV – Montpellier ethics committee. It is conducted notably in accordance with the Declaration of Helsinki and General Data Protection Regulation (GDPR). Study data and findings will be published in peer-reviewed medical journals. We also plan to present the study and all data at national congresses and conferences. Registration: ClinicalTrials.gov ID
NCT04133077; registered on October 21, 2019.
Collapse
Affiliation(s)
- Hugo Veyssière
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011, France
| | - Judith Passildas
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011, France
| | - Angeline Ginzac
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011, France
| | - Sejdi Lusho
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011, France
| | - Yannick Bidet
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Département d'oncogénétique, Laboratoire d'Oncologie Moléculaire, Centre Jean Perrin, Clermont-Ferrand, 63011, France
| | - Ioana Molnar
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011, France
| | - Maureen Bernadach
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011, France.,Département d'Oncologie Médicale, Centre Jean Perrin, Clermont-Ferrand, 63011, France
| | - Mathias Cavaille
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Département d'oncogénétique, Laboratoire d'Oncologie Moléculaire, Centre Jean Perrin, Clermont-Ferrand, 63011, France
| | - Nina Radosevic-Robin
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Département d'anatomie et de cytologie pathologiques, Centre Jean Perrin, Clermont-Ferrand, 63011, France
| | - Xavier Durando
- Université Clermont Auvergne, INSERM UMR 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Division de Recherche Clinique, Délégation Recherche Clinique & Innovation, Centre Jean Perrin, Clermont-Ferrand, 63011, France.,Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011, France.,Département d'Oncologie Médicale, Centre Jean Perrin, Clermont-Ferrand, 63011, France
| |
Collapse
|
22
|
Ouled Dhaou M, Kossai M, Morel AP, Devouassoux-Shisheboran M, Puisieux A, Penault-Llorca F, Radosevic-Robin N. Zeb1 expression by tumor or stromal cells is associated with spatial distribution patterns of CD8+ tumor-infiltrating lymphocytes: a hypothesis-generating study on 113 triple negative breast cancers. Am J Cancer Res 2020; 10:3370-3381. [PMID: 33163276 PMCID: PMC7642672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2020] [Accepted: 09/08/2020] [Indexed: 06/11/2023] Open
Abstract
Spatial organization of tumor microenvironment (TME) may influence tumor response to immunomodulatory therapies. Zeb1 is a driver of epithelial-mesenchymal transition, with several roles in immune cell development, however its role in shaping of the immune TME is not fully explored. We conducted a pre-multiplex spatial analysis study to verify whether Zeb1 influences spatial distribution of tumor-infiltrating lymphocytes (TILs) in triple negative breast cancer (TNBC). We applied single and double immunohistochemistry to analyze spatial relationships between CD8+, FoxP3+ and CD20+ tumor-infiltrating lymphocytes (TILs) and the cells expressing Zeb1 in formalin-fixed, paraffin-embedded surgical specimens of 113 TNBCs. 15.5% of cases had Zeb1+ tumor cells and 72.8% of cases had stroma rich in Zeb1+ cells. Low density of intratumoral CD8+ TILs was observed in almost all TNBCs with high or moderate Zeb1+ expression in tumor cells (22/23 cases, 95.6%), and in 90.4% of TNBCs (75/83 cases) with stroma rich in Zeb1+ cells. On the other side, a majority of TNBCs with stroma rich in Zeb1+ cells had high density of stromal CD8+ TILs (55/83 cases, 66.3%). These associations were not observed between Zeb1-expressing cells and FoxP3+ or CD20+ TILs. This in situ analysis showed specific spatial relationship between tumor or stromal Zeb1+ cells and CD8+ TILs, which need to be validated in other cohorts. Zeb1 was highlighted both as a marker of tumor cell EMT and of tumor stroma richness in mesenchymal cells. Several hypotheses about causes of the observed relationship between Zeb1 and TILs are generated and the approaches to verify them discussed. Zeb1 is worth further investigation as a potential biomarker of intratumor immunosuppression of TNBC and of its response to immunotherapies.
Collapse
Affiliation(s)
- Mona Ouled Dhaou
- University Clermont Auvergne, INSERM U1240, Centre Jean PerrinClermont-Ferrand, France
| | - Myriam Kossai
- University Clermont Auvergne, INSERM U1240, Centre Jean PerrinClermont-Ferrand, France
| | - Anne-Pierre Morel
- University Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon Berard, Cancer Research Center of LyonLyon, France
| | | | - Alain Puisieux
- University Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon Berard, Cancer Research Center of LyonLyon, France
- Institut CurieParis, France
| | | | - Nina Radosevic-Robin
- University Clermont Auvergne, INSERM U1240, Centre Jean PerrinClermont-Ferrand, France
| |
Collapse
|
23
|
Jouberton E, Schmitt S, Chautard E, Maisonial-Besset A, Roy M, Radosevic-Robin N, Chezal JM, Miot-Noirault E, Bouvet Y, Cachin F. [ 18F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer. EJNMMI Res 2020; 10:2. [PMID: 31907640 PMCID: PMC6944726 DOI: 10.1186/s13550-019-0587-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Accepted: 12/12/2019] [Indexed: 12/12/2022] Open
Abstract
PURPOSE Pathological complete response to the neoadjuvant therapy (NAT) for triple negative breast cancer (TNBC) is predictive of prolonged patient survival. Methods for early evaluation of NAT efficiency are still needed, in order to rapidly adjust the therapeutic strategy in case of initial non-response. One option for this is molecular imaging of apoptosis induced by chemotherapy. Therefore, we investigated the capacity of [18F]ML-10 PET imaging, an apoptosis radiotracer, to detect tumor cell apoptosis and early predict the therapeutic response of human TNBC. RESULTS Initially, the induction of apoptosis by different therapies was quantified. We confirmed, in vitro, that paclitaxel or epirubicin, the fundamental cytotoxic drugs for breast cancer, induce apoptosis in TNBC cell lines. Exposure of TNBC models MDA-MB-231 and MDA-MB-468 to these drugs induced a significant increase (p < 0.01) of the apoptotic hallmarks: DNA fragmentation, membrane phospholipid scrambling, and PARP activation. Secondarily, apoptotic fraction was compared to the intracellular accumulation of the radiotracer. [18F]ML-10 accumulated in the apoptotic cells after 72 h of treatment by paclitaxel in vitro; this accumulation positively correlated with the apoptotic fraction. In vivo, [18F]ML-10 was rapidly cleared from the nontarget organs and mainly eliminated by the kidneys. Comparison of the in vivo [18F]FDG, [18F]FMISO, and [18F]ML-10 uptakes revealed that the tumor accumulation of [18F]ML-10 was directly related to the tumor hypoxia level. Finally, after the in vivo treatment of TNBC murine xenografts by paclitaxel, apoptosis was well induced, as demonstrated by the cleaved caspase-3 levels; however, no significant increase of [18F]ML-10 accumulation in the tumors was observed, either on day 3 or day 6 after the end of the treatment. CONCLUSIONS These results highlighted that PET imaging using [18F]ML-10 allows the visualization of apoptotic cells in TNBC models. Nevertheless, the increase of the chemotherapy-induced apoptotic response when using paclitaxel could not be assessed using this radiotracer in our mouse model.
Collapse
Affiliation(s)
- Elodie Jouberton
- Service de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France
- Zionexa, Aubière, France
| | - Sébastien Schmitt
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France
| | - Emmanuel Chautard
- Département de Pathologie, Centre Jean Perrin, Clermont-Ferrand, France
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France
| | - Aurélie Maisonial-Besset
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France
| | - Marie Roy
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Département de Pathologie, Centre Jean Perrin, Clermont-Ferrand, France
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France
| | - Jean-Michel Chezal
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France
| | - Elisabeth Miot-Noirault
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France
| | | | - Florent Cachin
- Service de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France.
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France.
- Centre de Lutte Contre le Cancer, Centre Jean Perrin, 58 rue Montalembert, 63011, Clermont-Ferrand, France.
| |
Collapse
|
24
|
Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Gastric Cancer 2020; 23:73-81. [PMID: 31267360 DOI: 10.1007/s10120-019-00983-3] [Citation(s) in RCA: 62] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2019] [Accepted: 06/25/2019] [Indexed: 02/07/2023]
Abstract
BACKGROUND The correlation between immune cells and the Lauren classification subtypes and their prognostic impact in advanced gastric cancer (AGC) are unknown. METHODS Circulating natural killer (NK) cells, CD4+ and CD8+ T cells, regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) were quantified in peripheral blood mononuclear cells (PBMCs) from 67 patients with untreated AGC enrolled in the PRODIGE 17-ACCORD 20 trial. CD56+ cells (NK), CD8+, and FoxP3+ (Treg) tumor-infiltrating lymphocytes (TILs) were assessed in tumor samples. RESULTS Circulating NK and Treg proportions were significantly lower in patients with diffuse/mixed-type AGC (n = 27) than those with intestinal type (n = 40; median 6.3% vs 11.5%; p = 0.02 and median 3.3% vs 5.2%; p = 0.03, respectively). Proportions of circulating MDSC, CD4+ and CD8+ T cells were not associated with one pathological type. Among tumor-infiltrating cells, CD8+ T cells, but not NK or FoxP3+ cells, were significantly lower in diffuse/mixed-type AGC (median 21 vs 59 cells/field; p = 0.009). Patients with high circulating NK cell counts (> 17%) had a better overall survival than those with < 17% (HR 0.40; 95% CI [0.15-1.06]; p = 0.04). Patients with high CD8+ TIL counts (> 31 cells/field) had significantly longer overall survival (HR 0.44; 95% CI [0.21-0.92]; p = 0.02). The prognostic value of CD8+ TILs was maintained after adjustment for confounding factors, including the Lauren classification (HR = 0.42; 95% CI [0.18-0.96]; p = 0.039). CONCLUSION Diffuse/mixed-type AGC has lower rates of CD8+ TILs and circulating NK cells and Tregs than the intestinal type. This "cold tumor" phenotype may be associated with a worse outcome.
Collapse
Affiliation(s)
- Simon Pernot
- Université de Paris, PARCC, INSERM, 75015, Paris, France. .,Hôpital Européen Georges-Pompidou, APHP; Department of GI oncology, Université de Paris, Paris, France.
| | - Magali Terme
- Université de Paris, PARCC, INSERM, 75015, Paris, France
| | - Nina Radosevic-Robin
- Department of Biopathology, Centre Jean Perrin and University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, France
| | - Florence Castan
- Biometrics Unit, Institut du Cancer Montpellier-Val d'Aurelle, Université de Montpellier, Montpellier, France
| | - Cécile Badoual
- Université de Paris, PARCC, INSERM, 75015, Paris, France.,Department of Pathology, Université de Paris, Sorbonne Paris Cité, Paris, France
| | | | - Fréderique Penault-Llorca
- Department of Biopathology, Centre Jean Perrin and University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, France
| | | | - Jaafar Bennouna
- Institut de Cancérologie de l'Ouest-Site René Gauducheau, Saint Herblain, France
| | | | | | | | - Emmanuelle Samalin
- Institut du Cancer Montpellier-Val d'Aurelle, Université de Montpellier, Montpellier, France
| | | | | | - Valérie Boige
- Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France
| | - Thibault Voron
- Université de Paris, PARCC, INSERM, 75015, Paris, France
| | | | - Eric Tartour
- Université de Paris, PARCC, INSERM, 75015, Paris, France
| | - Sophie Gourgou
- Biometrics Unit, Institut du Cancer Montpellier-Val d'Aurelle, Université de Montpellier, Montpellier, France
| | - David Malka
- Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France
| | - Julien Taieb
- Université de Paris, PARCC, INSERM, 75015, Paris, France.,Hôpital Européen Georges-Pompidou, APHP; Department of GI oncology, Université de Paris, Paris, France
| |
Collapse
|
25
|
Radosevic-Robin N, Reeves J, Leroy K, Duruisseaux M, Morel P, Bhagat M, Penault-Llorca F, Damotte D, Goldwasser F, Brindel A, Cumberbatch M, Ong S, Lopez J, Warren S. Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz447.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Yakhni M, Briat A, El Guerrab A, Furtado L, Kwiatkowski F, Miot-Noirault E, Cachin F, Penault-Llorca F, Radosevic-Robin N. Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance. Am J Cancer Res 2019; 9:1043-1060. [PMID: 31218111 PMCID: PMC6556597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 04/01/2019] [Indexed: 06/09/2023] Open
Abstract
Triple negative breast cancers (TNBC) without BRCA1/2 gene mutation or BRCAness are nowadays the breast malignancies most difficult to treat. Improvement of their treatment, for all phases of the disease, is an important unmet medical need. We analyzed the effect of homoharringtonine (HHT), a natural protein synthesis inhibitor approved for treatment of chronic myeloid leukemia, on four cell lines representing aggressive, BRCA1/2 non-mutated, TNBC genomic categories. We show that HHT inhibits in vitro growth of all cell lines for more than 80%, after 48-72 h exposure to 20-100 ng/mL, the concentrations achievable in human plasma after subcutaneous administration of the drug. HHT, at 100 ng/mL, strongly reduced levels of a major TNBC survival factor, anti-apoptotic protein Mcl-1, after only 2 h of exposure, in all cell lines except MDA-MB-231. Other anti-apoptotic proteins, Bcl-2, survivin and XIAP, were also strongly downregulated. Moreover, in vivo growth of the least sensitive cell line to HHT in vitro, MDA-MB-231, was inhibited for 36.5% in mice, by 1 mg/kg of the drug, given subcutaneously, bi-daily, over 7 days. These results demonstrate marked antineoplastic activity of homoharringtonine in TNBC, making further development of the drug in this disease highly warranted.
Collapse
Affiliation(s)
- Mohamad Yakhni
- University Clermont Auvergne, INSERM U1240Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont-Ferrand, France
| | - Arnaud Briat
- University Clermont Auvergne, INSERM U124058 Rue Montalembert, 63011 Clermont-Ferrand, France
| | - Abderrahim El Guerrab
- University Clermont Auvergne, INSERM U124058 Rue Montalembert, 63011 Clermont-Ferrand, France
| | - Ludivine Furtado
- University Clermont Auvergne, INSERM U1240Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont-Ferrand, France
| | - Fabrice Kwiatkowski
- University Clermont Auvergne, INSERM U1240Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont-Ferrand, France
| | - Elisabeth Miot-Noirault
- University Clermont Auvergne, INSERM U124058 Rue Montalembert, 63011 Clermont-Ferrand, France
| | - Florent Cachin
- University Clermont Auvergne, INSERM U1240Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont-Ferrand, France
| | - Frederique Penault-Llorca
- University Clermont Auvergne, INSERM U1240Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- University Clermont Auvergne, INSERM U1240Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont-Ferrand, France
| |
Collapse
|
27
|
Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo PE, Azria D, Pèlegrin A, Larbouret C, Chardès T. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int J Cancer 2019; 145:1838-1851. [PMID: 30882895 DOI: 10.1002/ijc.32273] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 02/20/2019] [Accepted: 03/01/2019] [Indexed: 12/17/2022]
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by poor response to chemotherapy and radiotherapy due to the lack of efficient therapeutic tools and early diagnostic markers. We previously generated the nonligand competing anti-HER3 antibody 9F7-F11 that binds to pancreatic tumor cells and induces tumor regression in vivo in experimental models. Here, we asked whether coupling 9F7-F11 with a radiosensitizer, such as monomethylauristatin E (MMAE), by using the antibody-drug conjugate (ADC) technology could improve radiation therapy efficacy in PDAC. We found that the MMAE-based HER3 antibody-drug conjugate (HER3-ADC) was efficiently internalized in tumor cells, increased the fraction of cells arrested in G2/M, which is the most radiosensitive phase of the cell cycle, and promoted programmed cell death of irradiated HER3-positive pancreatic cancer cells (BxPC3 and HPAC cell lines). HER3-ADC decreased the clonogenic survival of irradiated cells by increasing DNA double-strand break formation (based on γH2AX level), and by modulating DNA damage repair. Tumor radiosensitization with HER3-ADC favored the inhibition of the AKT-induced survival pathway, together with more efficient caspase 3/PARP-mediated apoptosis. Incubation with HER3-ADC before irradiation synergistically reduced the phosphorylation of STAT3, which is involved in chemoradiation resistance. In vivo, the combination of HER3-ADC with radiation therapy increased the overall survival of mice harboring BxPC3, HPAC cell xenografts or patient-derived xenografts, and reduced proliferation (KI67-positive cells). Combining auristatin radiosensitizer delivery via an HER3-ADC with radiotherapy is a new promising therapeutic strategy in PDAC.
Collapse
Affiliation(s)
- Laura Bourillon
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Céline Bourgier
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France.,Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Nadège Gaborit
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Véronique Garambois
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Eva Llès
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Alexandre Zampieri
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Charline Ogier
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Marta Jarlier
- Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Nina Radosevic-Robin
- Department of Biopathology, Jean Perrin Comprehensive Cancer Center and INSERM/UCA UMR 1240, 63011, Clermont-Ferrand, France
| | - Béatrice Orsetti
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Hélène Delpech
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Charles Theillet
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Pierre-Emmanuel Colombo
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France.,Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - David Azria
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France.,Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - André Pèlegrin
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Christel Larbouret
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France
| | - Thierry Chardès
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France.,Centre National de la Recherche Scientifique (CNRS), Paris, France
| |
Collapse
|
28
|
Finck W, Passildas J, Poirier C, Kwiatkowski F, Abrial C, Durando X, Penault-Llorca F, Radosevic-Robin N. Abstract P5-12-09: The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-12-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Durable responses of triple negative breast cancer (TNBC) to pembrolizumab (anti-PD-1) or atezolizumab (anti-PD-L1) have been reported in the metastatic setting. Moreover, it is currently being hypothesized that immune checkpoint inhibitors might be more effective in the neoadjuvant setting, due to better preserved anti-tumor immunity in early TN disease. However, biomarkers predictive of response to anti-PD-1 or anti-PD-L1 agents, as well as biomarker-based strategies for testing those drugs in the neoadjuvant setting are still lacking. We evaluated PD-L1 protein expression and the composition of tumor-infiltrating lymphocytes (TILs) in untreated TNBC, in order to get a better insight into the TNBC sub-population(s) which would be suitable for neoadjuvant anti-PD-1 or anti-PD-L1 therapy evaluation. Methods: TNBC patients consecutively treated at the Jean Perrin Comprehensive Cancer Centre (Clermont-Ferrand, France), from 01/01/2010 to 12/31/2014, were included. FFPE tumor tissues were assessed for PD-L1 expression by immunohistochemical (IHC) laboratory-developed test (clone 28-8, Abcam), in tumor cells (tPD-L1) and in TILs. Positivity cut-offs evaluated were ≥1%, ≥5% and ≥10%. The amount CD8+, CD4+, FoxP3+ or PD-1+ TILs was determined by counting those cells, detected by IHC methods, within 5 consecutive HPFs (x400), from tumor invasive front toward tumor center. Clinical disease stage was determined using the TNM system. Results: One hundred and two TNBCs were assessed. There were 28.4%, 23.5% or 16.7% tPD-L1-positive cases (cs), for cut-offs ≥1%, ≥5% or ≥10%, respectively. Similarly, 32.4%, 15.7% or 5.9% of cs were positive for PD-L1 in TILs, using the same cut-offs. With ≥5% as cut-off, positivity for tPD-L1 significantly correlated with the amount of CD8+ (p=0.023), FoxP3+ (p=0.0036) or PD-1+ TILs (p=0.043). The same cut-off, applied to TILs, revealed significant correlations between PD-L1 positivity and the amount of each CD8+, CD4+ or PD-1+ TILs (p=0.025, 0.039 and 0.0042, respectively). Interestingly, when the ≥5% cut-off was used, tumors of T2 size were most frequently tPD-L1+ (11/41 cs, 26.8%), compared with the T1 (3/35 cs, 8.6%) and T3+T4 (3/18 cases, 16.7%) (p=0.04). With regards to TILs, with the ≥5% cut-off, the PD-L1+ cases belonged exclusively to the T1+T2 group (15/76), whereas the T3+T4 group was PD-L1-negative (0/18 cs). Other two cut-offs revealed only occasional correlations. Conclusion: This single-center, real-world TNBC cohort contained a high number of smaller tumors (T1-T2). The IHC-based PD-L1 assessment, with ≥5% as the positivity cut-off, revealed that approximately 1/4 of TNBC could be candidates for neoadjuvant anti-PD-1/anti-PD-L1 approaches. Combined with the amount of CD8+ and PD-1+ TILs, tumor PD-L1 positivity might make an easy-to-use composite biomarker for the 1st-level patient selection for PD-1 or PD-L1 inhibitors in neoadjuvant TNBC treatment. The 2nd level could exploit, for example, the assessment of mutation burden in tumors with low tPD-L1 or amount of CD8+ or PD-1+ TILs. Such tumors might be more frequent among larger TNBC (T3-T4).
Citation Format: Finck W, Passildas J, Poirier C, Kwiatkowski F, Abrial C, Durando X, Penault-Llorca F, Radosevic-Robin N. The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-09.
Collapse
Affiliation(s)
- W Finck
- Centre Jean Perrin, Clermont-Ferrand, France; UMR1240 INSERM/UCA, Centre Jean Perrin, Clermont-Ferrand, France
| | - J Passildas
- Centre Jean Perrin, Clermont-Ferrand, France; UMR1240 INSERM/UCA, Centre Jean Perrin, Clermont-Ferrand, France
| | - C Poirier
- Centre Jean Perrin, Clermont-Ferrand, France; UMR1240 INSERM/UCA, Centre Jean Perrin, Clermont-Ferrand, France
| | - F Kwiatkowski
- Centre Jean Perrin, Clermont-Ferrand, France; UMR1240 INSERM/UCA, Centre Jean Perrin, Clermont-Ferrand, France
| | - C Abrial
- Centre Jean Perrin, Clermont-Ferrand, France; UMR1240 INSERM/UCA, Centre Jean Perrin, Clermont-Ferrand, France
| | - X Durando
- Centre Jean Perrin, Clermont-Ferrand, France; UMR1240 INSERM/UCA, Centre Jean Perrin, Clermont-Ferrand, France
| | - F Penault-Llorca
- Centre Jean Perrin, Clermont-Ferrand, France; UMR1240 INSERM/UCA, Centre Jean Perrin, Clermont-Ferrand, France
| | - N Radosevic-Robin
- Centre Jean Perrin, Clermont-Ferrand, France; UMR1240 INSERM/UCA, Centre Jean Perrin, Clermont-Ferrand, France
| |
Collapse
|
29
|
Penault-Llorca F, Radosevic-Robin N. Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view. Transl Lung Cancer Res 2018; 7:716-721. [PMID: 30505716 PMCID: PMC6249617 DOI: 10.21037/tlcr.2018.09.26] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Accepted: 09/26/2018] [Indexed: 12/17/2022]
Abstract
In non-small cell lung cancer (NSCLC), the pathologist has contributed to the development of personalized medicine from the determination of the right histological type to EGFR and ALK/ROS1 molecular screening for targeted therapies. With the development of immunotherapies, pathologists intervene forefront with programmed death-ligand 1 (PD-L1) immunohistochemical testing, companion test for pembrolizumab monotherapy, first line and complementary test to the other programmed cell death-1 (PD-1) PD-L1 inhibitors. Recently, tumor mutational burden has emerged as a promising tool to evaluate sensitivity to immunotherapy (IO). The pathologist has a crucial role in the setting of tumor mutational burden (TMB) testing for the selection and the preparation of the sample for high throughput molecular analysis, and in the first steps of the next-generation sequencing (NGS) workflow.
Collapse
|
30
|
Bingula R, Filaire M, Radosevic-Robin N, Berthon JY, Bernalier-Donadille A, Vasson MP, Thivat E, Kwiatkowski F, Filaire E. Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma: Study protocol for case-control observational trial. Medicine (Baltimore) 2018; 97:e13676. [PMID: 30558074 PMCID: PMC6320062 DOI: 10.1097/md.0000000000013676] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Accepted: 11/22/2018] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Several studies have confirmed the important role of the gut microbiota in the regulation of immune functions and its correlation with different diseases, including cancer. While brain-gut and liver-gut axes have already been demonstrated, the existence of a lung-gut axis has been suggested more recently, with the idea that changes in the gut microbiota could affect the lung microbiota, and vice versa. Likewise, the close connection between gut microbiota and cancer of proximal sites (intestines, kidneys, liver, etc.) is already well established. However, little is known whether there is a similar relation when looking at world's number one cause of death from cancer-lung cancer. OBJECTIVE Firstly, this study aims to characterise the gut, lung, and upper airways (UAs) microbiota in patients with non-small cell lung cancer (NSCLC) treated with surgery or neoadjuvant chemotherapy plus surgery. Secondly, it aims to evaluate a chemotherapy effect on site-specific microbiota and its influence on immune profile. To our knowledge, this is the 1st study that will analyse multi-site microbiota in NSCLC patients along with site-specific immune response. METHODS The study is a case-controlled observational trial. Forty NSCLC patients will be divided into 2 groups depending on their anamnesis: Pchir, patients eligible for surgery, or Pct-chir, patients eligible for neoadjuvant chemotherapy plus surgery. Composition of the UAs (saliva), gut (faeces), and lung microbiota (from broncho-alveolar lavage fluid (BALF) and 3 lung pieces: "healthy" tissue distal to tumour, peritumoural tissue and tumour itself) will be analysed in both groups. Immune properties will be evaluated on the local (evaluation of the tumour immune cell infiltrate, tumour classification and properties, immune cell phenotyping in BALF; human neutrophil protein (HNP) 1-3, β-defensin 2, and calprotectin in faeces) and systemic level (blood cytokine and immune cell profile). Short-chain fatty acids (SCFAs) (major products of bacterial fermentation with an effect on immune system) will be dosed in faecal samples. Other factors such as nutrition and smoking status will be recorded for each patient. We hypothesise that smoking status and tumour type/grade will be major factors influencing both microbiota and immune/inflammatory profile of all sampling sites. Furthermore, due to non-selectivity, the same effect is expected from chemotherapy.
Collapse
Affiliation(s)
- Rea Bingula
- University of Clermont-Auvergne, UMR 1019 INRA-UCA, Human Nutrition Unit (UNH), Clermont-Ferrand
| | - Marc Filaire
- University of Clermont-Auvergne, UMR 1019 INRA-UCA, Human Nutrition Unit (UNH), Clermont-Ferrand
- Centre Jean Perrin, Thoracic Surgery Department, Clermont-Ferrand
| | - Nina Radosevic-Robin
- INSERM U1240, University Clermont Auvergne, Centre Jean Perrin, Department of Pathology, Clermont-Ferrand
| | | | | | - Marie-Paule Vasson
- University of Clermont-Auvergne, UMR 1019 INRA-UCA, Human Nutrition Unit (UNH), Clermont-Ferrand
- Centre Jean Perrin, CHU Gabriel-Montpied, Clinical Nutrition Unit, Clermont-Ferrand
| | - Emilie Thivat
- University of Clermont-Auvergne, INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont-Ferrand
- Centre Jean Perrin, Clinical Research Department, Clermont-Ferrand, France
| | - Fabrice Kwiatkowski
- University of Clermont-Auvergne, INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont-Ferrand
- Centre Jean Perrin, Clinical Research Department, Clermont-Ferrand, France
| | - Edith Filaire
- University of Clermont-Auvergne, UMR 1019 INRA-UCA, Human Nutrition Unit (UNH), Clermont-Ferrand
- Greentech SA, Biopole Clermont-Limagne, Saint-Beauzire
| |
Collapse
|
31
|
Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D’Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol 2018; 52:16-25. [DOI: 10.1016/j.semcancer.2017.10.003] [Citation(s) in RCA: 232] [Impact Index Per Article: 38.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Accepted: 10/04/2017] [Indexed: 12/20/2022]
|
32
|
Radosevic-Robin N, Ong S, Warren S, Kossai M, Godfraind C, Masson M, Janicot H, Merle P, Dubray-Longueras P, Durando X, Morel P, Cesano A, Penault-Llorca F. Gene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.121] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Yakhni M, Briat A, Miot-Noirault E, Cachin F, Penault-Llorca F, Radosevic-Robin N. Abstract 5803: Homoharringtonine, a natural protein synthesis inhibitor, inhibits growth of triple negative breast cancer in vitro and in vivo. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Triple negative breast cancer (TNBC) is a heterogeneous disease for which new therapeutic approaches are urgently needed. Homoharringtonine (HHT) is a protein synthesis inhibitor clinically approved in chronic myeloid leukemia. Its multi-factor mechanism of action includes downregulation of short-lived cellular proteins like Mcl-1. As increased protein synthesis lies behind several hallmarks of cancer present in TNBC, we investigated the effect of HHT on TNBC in vitro and in vivo.
Methods: TNBC cell lines CAL-51, MDA-MB-231 and MDA-MB-468, representative of aggressive, BRCA1 non-mutated TNBC (Lehmann, J Clin Invest 2011) were used. HHT was provided by LeukePharma, Houston, TX, USA. Cell viability was assessed by sulphorhodamine B assay. Number of cells in different cell cycle phases or in apoptosis was determined by flow cytometry. Protein expression was evaluated by western blot. For in vivo experiments, xenografts of MDA-MB-231 were established in Swiss nu/nu mice, treated for 7 days by subcutaneous HHT (1 mg/kg, bi-daily), and analyzed on day 10. Evaluation of HHT on MDA-MB-468 and CAL-51 xenografts is ongoing.
Results: Already after 24h of exposure to 100 ng/ml HHT (mean plasma HHT concentration after 5 mg/m2/day in humans (Sentenac S et al, Blood 2003)), viability of CAL-51 and MDA-MB-468 cells was strongly reduced (10.4±1.0% and 19.2±2.2% of control, respectively). This inhibition level was obtained in MDA-MB-231 cells only after 72h (18.7±4.8%). After 48h in 100 ng/ml HHT, MDA-MB-231 and -468 cells accumulated in the S phase of the cell cycle, whereas the CAL-51 accumulated in the G1/0 phase. This was associated with an increase of apoptosis in CAL-51 (42.0±2.4% vs 9.2±1.3%, untreated vs treated cells, respectively) and in MDA-MB-468 (24.2±2.8% vs 12.2±3.6%) but not in MDA-MB-231 (9.0±2.2% vs 3.6±1.7%). Concordantly, 100 ng/ml of HHT induced, after only 2h, a marked decrease of the level of anti-apoptotic proteins Mcl-1, Bcl-2, survivin and XIAP in CAL-51 and MDA-MB-468 cells, which preceded by 2h the reduction of caspase-3 level. No change in expression of those proteins was observed in MDA-MB-231 during all 48h of exposure to HHT. On the other side, the quantity of phosphorylated S6 increased in MDA-MB-231 but decreased in CAL-51 and MDA-MB-468 already after 24h of incubation with 100 ng/ml HHT. In vivo, HHT reduced growth of MDA-MB-231 xenografts for 36.5% (tumor volume on day 10: 230.4±27.7% mm3 vs 146.2±15.5% mm3, untreated vs treated, respectively).
Conclusion: HHT exerts cytotoxic action on TNBC cell lines CAL-51 and MDA-MB-468 whereas its effect on MDA-MB-231 is dominantly cytostatic. Because of its capacity to rapidly reduce the levels of anti-apoptotic proteins, HHT is worth further studies as potential sensitizer of TNBC to chemo- and/or targeted therapy.
Citation Format: Mohamad Yakhni, Arnaud Briat, Elisabeth Miot-Noirault, Florent Cachin, Frederique Penault-Llorca, Nina Radosevic-Robin. Homoharringtonine, a natural protein synthesis inhibitor, inhibits growth of triple negative breast cancer in vitro and in vivo [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5803.
Collapse
Affiliation(s)
- Mohamad Yakhni
- 1INSERM U1240/University Clermont Auvergne, Centre Jean Perrin, Clermont-Ferrand, France
| | - Arnaud Briat
- 2INSERM U1240/University Clermont Auvergne, Clermont-Ferrand, France
| | | | - Florent Cachin
- 1INSERM U1240/University Clermont Auvergne, Centre Jean Perrin, Clermont-Ferrand, France
| | | | - Nina Radosevic-Robin
- 1INSERM U1240/University Clermont Auvergne, Centre Jean Perrin, Clermont-Ferrand, France
| |
Collapse
|
34
|
Bayol B, Tixier-Deves L, Dauplat M, Kwiatkowski F, Cayre A, Abrial C, Azria D, Penault-Llorca F, Radosevic-Robin N. Abstract P4-15-03: Tumor-infiltrating lymphocytes in breast ductal carcinoma in situ: Correlations with tumor pathobiology in a French cohort of 495 cases (BONBIS). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-15-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Numerous studies have shown important impact of tumor-infiltrating lymphocytes (TILs) on natural or therapeutically-modified evolution of invasive breast cancer (IBC), however knowledge about TIL role in breast ductal carcinoma in situ (DCIS) is still limited. Because of the lack of reliable prognostic parameters, DCIS treatment is much less personalized than IBC therapy. BONBIS is a phase 3 French multicenter randomized trial designed to compare 2 schemes of adjuvant radiotherapy (adjRT) for DCIS (Azria et al, ASCO meeting 2011, TPS 131). It is accompanied by a translational study of DCIS pathobiology, aimed to discover predictive or prognostic biomarkers. Here we present results of TIL density (TIL-d) assessment, its correlation with pathobiology of the lesions and preliminary clues for further biomarker search in this DCIS cohort. Methods: Formalin-fixed, paraffin-embedded DCIS surgical specimens, obtained before adjRT, were prospectively collected and centrally reviewed for histology (architectural pattern, nuclear grade, proliferation, presence of necrosis), receptor status (ER, PR, HER2) and TIL-d. TIL-d was assessed on H&E-stained DCIS sections and reported as percentage of the DCIS specialized stroma area occupied by lymphocytes, lympho-plasmocytes and plasmocytes. Tumors were classified using the St Gallen 2011 criteria for IBC (PMID 21709140). For purpose of this study, the HER2+ category included all cases with HER2 protein expression scored 2+ and 3+, irrespective of the ERBB2 amplification status. Results: TIL-d was assessed in 495 cases, with distribution as follows: 0-4% TILs (D1): 85.5% (n=423); 5-9% TILs (D2): 9.3% (n=46); ≥10% TILs (D3): 5.2% (n=26). Molecular subclasses of those cases were: luminal A (LumA): 39% (n=192); luminal B (LumB): 25.5% (n=126), HER2+: 28.5% (n=141) and triple-negative (TN): 7% (n=33). TIL-d significantly correlated with molecular subclass: ≥5% TILs (D2) were found in 39.4% (13/33) TN, 22.7% (32/141) HER2+, 18.2% (23/126) LumB and only in 1% (2/192) LumA cases (p<10-7). TIL-d of ≥10% (D3) was found only in 26/495 cases (5.2%) and of ≥50% only in one. Similarly to D2, D3 was most frequent in TN, and then in HER2+, LumB and LumA lesions (15%, 9.2%, 7.1%, 0.5%, resp., p<10-7). TIL-d significantly correlated with 2 architectural patterns: positively with solid (38.8%, 52.2% and 60% of D1, D2 and D3 within the solid lesions, resp., p=0.03) but negatively with cribriform (53%, 32.6% and 28% of D1, D2 and D3 within the cribriform lesions, resp., p=0.0027). Finally, the presence of necrosis was significantly associated with TIL-d of ≥5% (65.7% vs 84.5%, D1 vs D2+D3, p=0.071). Due to still short follow-up, the analysis of predictive factors for survival or adjRT benefit was not performed. Conclusion: This DCIS cohort is characterized by low density of TILs. Richer infiltration by TILs (≥10%) was found, as reported in IBC, in TN and HER2+ lesions, however ≥50% TILs was an extremely rare finding. Interestingly, the LumB cases had TIL-d comparable to the HER2+ cases. The associations between ≥10% TILs and molecular subclass or with DCIS architecture will be evaluated in the future as biomarkers of adjRT impact on survival in this cohort.
Citation Format: Bayol B, Tixier-Deves L, Dauplat M, Kwiatkowski F, Cayre A, Abrial C, Azria D, Penault-Llorca F, Radosevic-Robin N. Tumor-infiltrating lymphocytes in breast ductal carcinoma in situ: Correlations with tumor pathobiology in a French cohort of 495 cases (BONBIS) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-15-03.
Collapse
Affiliation(s)
- B Bayol
- Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Institute Paoli-Calmettes, Marseilles, France; **Equal Contribution University of Montpellier, INSERM U1194, Institute for Cancer Research of Montpellier, Montpellier, France; **Equal Contribution University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Clermont-Ferrand, France
| | - L Tixier-Deves
- Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Institute Paoli-Calmettes, Marseilles, France; **Equal Contribution University of Montpellier, INSERM U1194, Institute for Cancer Research of Montpellier, Montpellier, France; **Equal Contribution University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Clermont-Ferrand, France
| | - M Dauplat
- Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Institute Paoli-Calmettes, Marseilles, France; **Equal Contribution University of Montpellier, INSERM U1194, Institute for Cancer Research of Montpellier, Montpellier, France; **Equal Contribution University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Clermont-Ferrand, France
| | - F Kwiatkowski
- Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Institute Paoli-Calmettes, Marseilles, France; **Equal Contribution University of Montpellier, INSERM U1194, Institute for Cancer Research of Montpellier, Montpellier, France; **Equal Contribution University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Clermont-Ferrand, France
| | - A Cayre
- Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Institute Paoli-Calmettes, Marseilles, France; **Equal Contribution University of Montpellier, INSERM U1194, Institute for Cancer Research of Montpellier, Montpellier, France; **Equal Contribution University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Clermont-Ferrand, France
| | - C Abrial
- Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Institute Paoli-Calmettes, Marseilles, France; **Equal Contribution University of Montpellier, INSERM U1194, Institute for Cancer Research of Montpellier, Montpellier, France; **Equal Contribution University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Clermont-Ferrand, France
| | - D Azria
- Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Institute Paoli-Calmettes, Marseilles, France; **Equal Contribution University of Montpellier, INSERM U1194, Institute for Cancer Research of Montpellier, Montpellier, France; **Equal Contribution University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Clermont-Ferrand, France
| | - F Penault-Llorca
- Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Institute Paoli-Calmettes, Marseilles, France; **Equal Contribution University of Montpellier, INSERM U1194, Institute for Cancer Research of Montpellier, Montpellier, France; **Equal Contribution University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Clermont-Ferrand, France
| | - N Radosevic-Robin
- Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Institute Paoli-Calmettes, Marseilles, France; **Equal Contribution University of Montpellier, INSERM U1194, Institute for Cancer Research of Montpellier, Montpellier, France; **Equal Contribution University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Clermont-Ferrand, France
| |
Collapse
|
35
|
Radosevic-Robin N, Cocco E, Privat M, Abrial C, Penault-Llorca F, Scaltriti M. Abstract P2-09-29: Potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy, revealed by genomic analyses and assessment of tumor-infiltrating lymphocytes. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-09-29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Epidermal growth factor receptor (EGFR) is expressed in ˜50% of triple negative breast cancer (TNBC) and has been proposed as a therapeutic target in this disease. However, trials testing EGFR blockade in TNBC failed to show significant clinical benefit. Probable reasons for such results were patient selection based on EGFR expression and the enrollment of heavily pretreated metastatic patients. Our team has conducted two neoadjuvant trials testing the activity of the anti-EGFR antibodies panitumumab (PTB) and cetuximab (CTX) combined with chemotherapy in locally advanced TNBC. Biomarkers predictive of pathological complete response (pCR) were the level of tumor cell EGFR protein expression and tumor-infiltrating lymphocytes' (TILs) profile (PMIDs 24827135, 26649807). The PTB-treated pts had a higher pCR rate (47%) than the CTX-treated pts (24%), but also a twice higher relapse rate, after 5 years of follow-up. Here we report results of genomic and TILs studies, performed in order to reveal possible determinants of recurrences in those trials. Methods: Tumor tissues sampled before and after neoadjuvant therapy (NAT) have been analyzed by next generation sequencing (NGS) using a targeted exome panel (MSK-IMPACT) of 410 cancer-related genes. Gene expression was evaluated by Affymetrix arrays. TIL density was assessed on pre-NAT samples according to Salgado et al, 2014 (PMID 25214542). The correlation between response, recurrences, genomic and TIL findings was analyzed in a case-by-case fashion. Results: Sixteen tumors that achieved pCR (PTB: 11, CTX: 5) and 23 non-pCR tumors (PTB: 11, CTX: 12) have been analyzed. For 14 non-pCR tumors (PTB: 6, CTX: 8) data have been obtained both from the pre-NAT and the post-NAT sample. Among those tumors, 6 recurred within 2 years after surgery (PTMB: 3, CTX: 3) and assays are on-going on several others that relapsed. Several genomic aberrations that potentially played a causative role in opposing to therapy were identified. We observed multiple mutations in the PI3K pathway in several non-pCR or relapsing pts. Interestingly, in a residual tumor (RT) of a non-pCR patient we found 3 different activating mutations in PIK3CA and one in PTEN. Another example of genomic selection induced by pharmacological pressure is the emergence of a HRAS G12S mutation in a RT after CTX. Additional novel findings include in-frame mutations and deletions in ARID1B and PARP1 amplification in non-pCR pts. Most of the tumors which recurred had ≤10% TILs (9/13) and only 4/13 had ≥30%. Among the tumors with a post-NAT RT but without recurrence, 17/33 had ≤10% TILs and 16/33 ≥30%. No particular link between TIL density and mutation pattern was observed. Conclusions: This is an example of a case-by-case approach where we captured the intrinsic inter-tumor heterogeneity, which is likely responsible for the different responses to EGFR-targeting in TNBC. Genes/pathways candidate of resistance to therapy are currently being validated.
Citation Format: Radosevic-Robin N, Cocco E, Privat M, Abrial C, Penault-Llorca F, Scaltriti M. Potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy, revealed by genomic analyses and assessment of tumor-infiltrating lymphocytes [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-09-29.
Collapse
Affiliation(s)
- N Radosevic-Robin
- University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| | - E Cocco
- University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| | - M Privat
- University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| | - C Abrial
- University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| | - F Penault-Llorca
- University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| | - M Scaltriti
- University Clermont Auvergne, INSERM U1240 "Molecular Imaging & Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
36
|
Beguinot M, Dauplat MM, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C, Penault-Llorca F, Radosevic-Robin N. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer 2018; 18:129. [PMID: 29394917 PMCID: PMC5797400 DOI: 10.1186/s12885-018-4013-6] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2016] [Accepted: 01/22/2018] [Indexed: 12/16/2022] Open
Abstract
Background Tumour-infiltrating lymphocytes (TILs) have been demonstrated to significantly influence prognosis and response to therapy of invasive breast cancer (IBC). Thus, it has been suggested that TIL density or/and immunophenotype could serve as biomarkers for selection of IBC patients for immunotherapy. However, much less is known about significance of TILs in breast ductal carcinoma in situ (DCIS). Methods We retrospectively investigated TIL density and immunophenotype in 96 pure DCIS and 35 microinvasive carcinomas (miCa). TIL density was assessed on H&E-stained breast biopsy sections as the percentage of tumour stromal area occupied by TILs, and classified into 4 grades: 0 (0%–9%), 1 (10–29%), 2 (30–49%) and 3 (50%–100%). TIL immunophenotype was assessed by immunohistochemistry for CD8, CD4, FoxP3, CD38 or CD20. Results Compared to pure DCIS, miCa contained significantly more cases with TIL density grade 3 (p = 0.028). Concordantly, CD8+, CD4+ and CD38+ cells were more numerous in miCa than in pure DCIS. In the pure DCIS subgroup with TIL density grades 2 and 3, all TIL subpopulations were more numerous than in the pure DCIS with TIL density grades 0 and 1, however the ratio between T-lymphocytes (CD8+ and CD4+) and B-lymphocytes (CD20+) was significantly lower (p = 0.029). On the other side, this ratio was significantly higher in miCa, in comparison with pure DCIS having TIL density grades 2 and 3 (p = 0.017). By cluster analysis of tumour cell pathobiological features we demonstrated similarity between miCa and the pure DCIS with TIL density grades 2 and 3. The only significant difference between those two categories was in the ratio of T- to B-TILs, higher in miCa. Conclusion Results indicate that TIL density level can distinguish 2 biologically different DCIS subgroups, one of which (DCIS with ≥30% TILs, the TIL-rich DCIS) is like miCa. Similarity of TIL-rich pure DCIS and miCa as well as the role of B-lymphocytes in DCIS invasiveness are worth further investigating with regards to the potential development of immunotherapy-based prevention of DCIS progression. Electronic supplementary material The online version of this article (10.1186/s12885-018-4013-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Marie Beguinot
- Department of Surgical Oncology, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63011, Clermont-Ferrand, France.,Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, BP392, 63011, Clermont-Ferrand, France.,Master Program « Biology & Health », University Paris-East Val-de-Marne (UPEC), 61 avenue du General de Gaulle, 94010, Creteil, France
| | - Marie-Melanie Dauplat
- Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, BP392, 63011, Clermont-Ferrand, France.,Present Address: Department of Pathology, Paoli-Calmettes Comprehensive Cancer Centre, 232 boulevard Sainte-Marguerite, 13009, Marseilles, France
| | - Fabrice Kwiatkowski
- Department of Clinical Research, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63011, Clermont-Ferrand, France.,University Clermont Auvergne, INSERM U1240, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63011, Clermont-Ferrand, France
| | - Guillaume Lebouedec
- Department of Surgical Oncology, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63011, Clermont-Ferrand, France
| | - Lucie Tixier
- Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, BP392, 63011, Clermont-Ferrand, France.,University Clermont Auvergne, INSERM U1240, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63011, Clermont-Ferrand, France
| | - Christophe Pomel
- Department of Surgical Oncology, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63011, Clermont-Ferrand, France.,University Clermont Auvergne, INSERM U1240, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63011, Clermont-Ferrand, France
| | - Frederique Penault-Llorca
- Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, BP392, 63011, Clermont-Ferrand, France.,University Clermont Auvergne, INSERM U1240, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63011, Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, BP392, 63011, Clermont-Ferrand, France. .,University Clermont Auvergne, INSERM U1240, Jean Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63011, Clermont-Ferrand, France.
| |
Collapse
|
37
|
Radosevic-Robin N, Cocco E, Won H, Berger M, Privat M, Abrial C, Penault-Llorca F, Scaltriti M. Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Abstract
Although immunohistochemical detection of the Ki67 antigen has been used for many years to assess cancer proliferation, this marker is still not recommended for routine use in clinical management of breast cancer. The major reason for this situation is a lack of a standardised procedure for Ki67 assessment as well as persistence of several issues of debate with regards to the Ki67 assay interpretation and the marker's clinical utility. Nowadays Ki67 assessment is principally used for estimation of prognosis and guiding the decision on adjuvant treatment choice, as well as for prediction of response to neoadjuvant treatment in ER+/HER2- breast cancer. In ER-/HER2+ and ER-/HER2- tumours, high post-neoadjuvant Ki67 index is associated with unfavourable prognosis. We review here the elements impacting analytical validity of the Ki67 immunohistochemical assay, the evidence of its clinical utility and the current recommendations for its use in breast cancer management.
Collapse
Affiliation(s)
- Frederique Penault-Llorca
- Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/Univerisity of Auvergne UMR1240, Clermont-Ferrand, France; School of Medicine, University of Auvergne, Clermont-Ferrand, France.
| | - Nina Radosevic-Robin
- Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/Univerisity of Auvergne UMR1240, Clermont-Ferrand, France
| |
Collapse
|
39
|
Radosevic-Robin N, Béguinot M, Penault-Llorca F. [Evaluation of the immune infiltrate in breast cancer]. Bull Cancer 2016; 104:52-68. [PMID: 27986267 DOI: 10.1016/j.bulcan.2016.11.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Accepted: 11/10/2016] [Indexed: 01/21/2023]
Abstract
Tumour-infiltrating lymphocytes (TIL) are major components of the immune/"inflammatory" infiltrate found in tumour microenvironment. They reflect the intensity and the quality of the immune reaction to cancer. In breast cancer, TIL density and phenotypic profile have been demonstrated to be predictive of response to neoadjuvant treatment and of patient outcome. TIL density, currently the best-developed TIL-related biomarker, is defined as the percentage of tumour stroma surface occupied by TIL. The baseline TIL density of 50% and higher is associated with particularly high rates of pathological complete response to neoadjuvant therapy in triple negative and HER2+ breast cancer, as well as with significantly better recurrence-free and overall survival. Similar predictive and prognostic value has been demonstrated for the ratio between the numbers of CD8+ and FoxP3+ TIL. TIL density and the CD8+/FoxP3+ ratio are promising biomarkers in breast cancer, which could be used in tailoring of neoadjuvant and adjuvant systemic therapy and in selection of patients for different immunotherapy modalities. This article reviews elements of the immune response to cancer, methods of TIL analysis, evidence of TIL' prognostic and predictive value in the current breast cancer management as well as the perspectives for use of TIL' characteristics as biomarkers in breast cancer immunotherapy.
Collapse
Affiliation(s)
- Nina Radosevic-Robin
- Centre Jean Perrin, département d'anatomie et de cytologie pathologiques, 58, rue Montalembert, 63011 Clermont-Ferrand, France; Inserm U1240 « Imagerie moléculaire et stratégies théranostiques (IMoST) », 58, rue Montalembert, 63011 Clermont-Ferrand, France.
| | - Marie Béguinot
- Centre Jean-Perrin, département de chirurgie oncologique, 58, rue Montalembert, 63011 Clermont-Ferrand, France
| | - Frédérique Penault-Llorca
- Centre Jean Perrin, département d'anatomie et de cytologie pathologiques, 58, rue Montalembert, 63011 Clermont-Ferrand, France; Inserm U1240 « Imagerie moléculaire et stratégies théranostiques (IMoST) », 58, rue Montalembert, 63011 Clermont-Ferrand, France; Université d'Auvergne, faculté de médecine, 28, place Henri-Dunant, 63000 Clermont-Ferrand, France
| |
Collapse
|
40
|
Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet JM, Pèlegrin A, Larbouret C, Robert B. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin Cancer Res 2016; 23:2806-2816. [DOI: 10.1158/1078-0432.ccr-16-1316] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Revised: 10/11/2016] [Accepted: 11/10/2016] [Indexed: 11/16/2022]
|
41
|
Dalenc F, Penault-Llorca F, Cohen M, Houvenaeghel G, Piat JM, Liegeois P, Puyuelo L, Suchaud JP, Zouai M, Lacroix-Triki M, Radosevic-Robin N, Benkanoun C, Attar-Rabia H, Chauvet MP, Gligorov J, Belkacemi Y. Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study. Clin Breast Cancer 2016; 17:107-116. [PMID: 27856201 DOI: 10.1016/j.clbc.2016.08.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 07/29/2016] [Accepted: 08/20/2016] [Indexed: 12/24/2022]
Abstract
BACKGROUND Most breast cancer (BC) tumors ≤10 mm have an excellent prognosis. The subgroups with a higher risk for distant recurrence requiring adjuvant systemic therapy are not precisely defined in current international guidelines. PATIENTS AND METHODS The OBSERVATOIRE DES PETITS CANCERS DU SEIN HER2 +/- (ODISSEE) study was a prospective, multicenter, cohort study that aimed to describe the daily adjuvant management and outcome of 616 patients with unifocal, invasive pT1a-b pN0 nonmetastatic BC who underwent surgery. RESULTS At the time of diagnosis, the median age of patients was 61 years. Tumor was detected on imaging or during a screening program in 397 patients (64.6%). Most patients (96%) underwent conservative surgery with sentinel node biopsy (89%), completed with axillary lymph node dissection in 15%. At inclusion, 82% of tumors were pT1b, 73% were pN0 (i-), 53% were Scarff-Bloom-Richardson Grade I, 91% were estrogen receptor (ER)-positive, 5% overexpressed/amplified HER2, and 5% were triple negative (TNBC). Adjuvant treatments were radiotherapy (95%), hormone therapy (82%), chemotherapy (7%), and trastuzumab (3.5%). In patients with TNBC and HER2-positive BC, chemotherapy and trastuzumab (if needed) were administered in 45% and 68%, respectively. After 5 years of follow-up, 7 patients had contralateral BC, 7 had locoregional recurrence, and 1 had distant metastasis. At 5 years, overall survival, disease-free survival, and recurrence-free survival were: 98.4% (96.9%-99.1%), 94.7% (92.4%-96.3%), and 97.1% (95.2%-98.2%), respectively. CONCLUSION This prospective cohort study showed that in France, the routine practice in pT1a-b pN0 breast cancers follows international standard guidelines for practice including conservative surgery followed by radiotherapy and endocrine therapy for ER-positive patients. Adjuvant chemotherapy with or without trastuzumab was used but their benefit in breast cancer of ≤10 mm remains controversial.
Collapse
Affiliation(s)
- Florence Dalenc
- Claudius Regaud Institute, Institut Universitaire du Cancer de Toulouse (UICT)-Oncopole, Department of Medical Oncology and Inserm UMR 1037, Team "Cholesterol Metabolism and Therapeutic Innovations", Cancer Research Center, Toulouse, France
| | | | - Monique Cohen
- Department of Surgery, Private Institute, Aubagne, France
| | | | | | | | - Laurent Puyuelo
- Department of Breast and Gynecologic Surgery, Union Clinic, Saint Jean, France
| | | | - Mohammed Zouai
- Department of Radiotherapy, Marie Curie Institute, Valence, France
| | - Magali Lacroix-Triki
- Claudius Regaud Institute, Institut Universitaire du Cancer de Toulouse (UICT)-Oncopole, Department of Medical Oncology and Inserm UMR 1037, Team "Cholesterol Metabolism and Therapeutic Innovations", Cancer Research Center, Toulouse, France
| | | | | | | | - Marie-Pierre Chauvet
- Department of Breast Surgery, Oscar Lambret Anti-Cancer Center-UNICANCER, Lille, France
| | - Joseph Gligorov
- Assistance Publique Hôpitaux de Paris (AP-HP), Department of Medical Oncology, Tenon Hospital, and University of Pierre et Marie Curie (UPMC), Paris
| | - Yazid Belkacemi
- Assistance Publique Hôpitaux de Paris (AP-HP), Department of Radiation Oncology and Henri Mondor Breast Center, INSERM U955 E07, and University of Paris-Est Créteil (UPEC), France.
| |
Collapse
|
42
|
Martín-Martín N, Piva M, Urosevic J, Aldaz P, Sutherland JD, Fernández-Ruiz S, Arreal L, Torrano V, Cortazar AR, Planet E, Guiu M, Radosevic-Robin N, Garcia S, Macías I, Salvador F, Domenici G, Rueda OM, Zabala-Letona A, Arruabarrena-Aristorena A, Zúñiga-García P, Caro-Maldonado A, Valcárcel-Jiménez L, Sánchez-Mosquera P, Varela-Rey M, Martínez-Chantar ML, Anguita J, Ibrahim YH, Scaltriti M, Lawrie CH, Aransay AM, Iovanna JL, Baselga J, Caldas C, Barrio R, Serra V, dM Vivanco M, Matheu A, Gomis RR, Carracedo A. Stratification and therapeutic potential of PML in metastatic breast cancer. Nat Commun 2016; 7:12595. [PMID: 27553708 PMCID: PMC4999521 DOI: 10.1038/ncomms12595] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 07/12/2016] [Indexed: 01/15/2023] Open
Abstract
Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target in aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast tumours is accompanied by the elevated PML expression and enhanced sensitivity to its inhibition. Interestingly, we find that STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification.
Collapse
Affiliation(s)
| | - Marco Piva
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Jelena Urosevic
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
| | - Paula Aldaz
- Oncology Area, Biodonostia Institute, 20014 San Sebastian, Spain
| | | | | | - Leire Arreal
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Verónica Torrano
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Ana R. Cortazar
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Evarist Planet
- Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
- School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland
| | - Marc Guiu
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
| | - Nina Radosevic-Robin
- ERTICa Research Group, University of Auvergne EA4677, Clermont-Ferrand, France
- Biodiagnostics Laboratory OncoGenAuvergne, Pathology Unit, Jean Perrin Comprehensive Cancer Center, 63000 Clermont-Ferrand, France
| | - Stephane Garcia
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, CNRS UMR 7258, Aix-Marseille University and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, 13288 Marseille, France
| | - Iratxe Macías
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Fernando Salvador
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
| | - Giacomo Domenici
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Oscar M. Rueda
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
| | | | | | | | | | | | | | - Marta Varela-Rey
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
| | - Maria Luz Martínez-Chantar
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
| | - Juan Anguita
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain
| | - Yasir H. Ibrahim
- Experimental Therapeutics Group, Vall d'Hebron University Hospital, 08035 Barcelona, Spain
- Weill Cornell Medicine, New York 10021, USA
| | - Maurizio Scaltriti
- Human Oncology and Pathogenesis Program, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 10065 New York, USA
| | - Charles H. Lawrie
- Oncology Area, Biodonostia Institute, 20014 San Sebastian, Spain
- IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain
| | - Ana M. Aransay
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
| | - Juan L. Iovanna
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, CNRS UMR 7258, Aix-Marseille University and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, 13288 Marseille, France
| | - Jose Baselga
- Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 10065 New York, USA
| | - Carlos Caldas
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
| | - Rosa Barrio
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Violeta Serra
- Experimental Therapeutics Group, Vall d'Hebron University Hospital, 08035 Barcelona, Spain
| | - Maria dM Vivanco
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
| | - Ander Matheu
- Oncology Area, Biodonostia Institute, 20014 San Sebastian, Spain
- IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain
| | - Roger R. Gomis
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| | - Arkaitz Carracedo
- CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain
- IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain
- Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), 48949 Leioa, Spain
| |
Collapse
|
43
|
Bozec A, Ebran N, Radosevic-Robin N, Chamorey E, Yahia HB, Marcie S, Gautier M, Penault-Llorca F, Milano G. Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer. Head Neck 2016; 39:151-159. [DOI: 10.1002/hed.24560] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Revised: 03/24/2016] [Accepted: 06/27/2016] [Indexed: 02/06/2023] Open
Affiliation(s)
- Alexandre Bozec
- University Institute of the Face and Neck; Nice cedex France
| | - Nathalie Ebran
- Department of Oncopharmacology; Antoine Lacassagne Comprehensive Cancer Centre; Nice cedex France
| | - Nina Radosevic-Robin
- Department of Pathology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- ERTICa Research Group; University of Auvergne; Clermont-Ferrand France
| | - Emmanuel Chamorey
- Department of Clinical Research; Innovation and Statistics (DRIS), Antoine Lacassagne Comprehensive Cancer Centre; Nice cedex France
| | - Hedi Ben Yahia
- Department of Oncopharmacology; Antoine Lacassagne Comprehensive Cancer Centre; Nice cedex France
| | - Serge Marcie
- Department of Physics; Antoine Lacassagne Comprehensive Cancer Centre; Nice cedex France
| | - Mathieu Gautier
- Department of Physics; Antoine Lacassagne Comprehensive Cancer Centre; Nice cedex France
| | - Frédérique Penault-Llorca
- Department of Pathology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- ERTICa Research Group; University of Auvergne; Clermont-Ferrand France
| | - Gérard Milano
- Department of Oncopharmacology; Antoine Lacassagne Comprehensive Cancer Centre; Nice cedex France
| |
Collapse
|
44
|
Beguinot-Cornillon M, Dauplat MM, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C, Penault-Llorca F, Radosevic-Robin N. Abstract 1465: Analysis of tumor-infiltrating lymphocytes (TILs) reveals biologically different subgroups of breast ductal carcinoma in situ. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-1465] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treatment of breast ductal carcinoma in situ (DCIS) aims to prevent invasive recurrence. Recent studies have shown an important impact of TILs on the outcome of invasive breast cancer, however their influence on breast DCIS prognosis has not been fully explored. In this study we investigated whether the amount and/or phenotype of TILs can help recognizing DCIS subgroups of different biology and recurrence risk.
Methods: The study included 134 patients, diagnosed and treated for a DCIS from 2001 to 2005 in our institution. Formalin-fixed and paraffin-embedded (FFPE) cancer tissue samples, taken before any treatment, were retrospectively collected. H&E whole tissue sections served for assessment of the cancer size, grade, histotype, architecture, mitotic index and amount of stromal lymphocytic (Ly) infiltrate. The latter was semi-quantitatively graded into 4 grades (0 - absent, 1 - mild, 2 - moderate, 3 - intense). Ly-phenotype was assessed by immunohistochemistry (IHC) on tissue microarrays (TMAs), constructed by sampling each case at the area of the densest Ly-infiltration (3 cores of 0.6 mm diameter per case). The number/mm2 of the CD8+, CD4+, FOXP3+, CD20+ and CD38+ mononuclear cells was determined. TMAs served also for estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67 IHC staining, as well as for HER2 amplification status.
Results: There were 97 DCIS and 37 microinvasive DCIS (micDCIS). The micDCIS displayed significantly more diffuse architecture, frequent HER2 amplification (HER2amp), higher grade, lower ER expression (0.029<p<0.044 for each) and more peritumoral Ly-infiltrate (grades 2+3, micDCIS vs DCIS, 51.5% vs. 39.0%, p = 0.036). All but CD20+ cells were more numerous in micDCIS than in DCIS (0.0016<p<0.05). Within the entire cohort, the cases having the (CD8+/CD4+):(CD20+/CD38+) ratio higher than 1 had a significantly greater risk of containing a microinvasive component (OR 3.47 (1.26-9.57), p = 0.029). Interestingly, that ratio was significantly higher (p = 0.012) in micDCIS than in the DCIS with grade 2 or 3 Ly-infiltrate (Ly-DCIS, n = 38). On the other side, there was no difference between micDCIS and Ly-DCIS in architecture, histograde, HER2amp rate and ER expression. Cluster analysis further confirmed significant similarities between micDCIS and Ly-DCIS, putting them both apart from non-Ly-DCIS (p = 0.0034).
The overall 10-year recurrence rate was 13% (18/134 pts). No parameter significantly correlated with recurrence risk, however the micDCIS have received significantly more treatment than DCIS (axillary lymphadenectomy (p<10-7), chemotherapy (p = 0.031) or hormonal therapy (p = 5.4×10-6)).
Conclusion: These results indicate that Ly-DCIS might be biologically and immunologically similar to micDCIS. TILs in DCIS are worth investigating in larger studies, as they could be a marker of microinvasion and help tailoring the initial treatment of the disease.
Citation Format: Marie Beguinot-Cornillon, Marie-Melanie Dauplat, Fabrice Kwiatkowski, Guillaume Lebouedec, Lucie Tixier, Christophe Pomel, Frederique Penault-Llorca, Nina Radosevic-Robin. Analysis of tumor-infiltrating lymphocytes (TILs) reveals biologically different subgroups of breast ductal carcinoma in situ. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1465.
Collapse
Affiliation(s)
- Marie Beguinot-Cornillon
- 1Surgical Oncology, Pathology, Jean Perrin Cancer Center (JPCC); ERTICa Research Team, University of Auvergne EA4677, Clermont-Ferrand; Master Program in Biology and Health Sciences, University Paris-East Val-de-Marne (UPEC), Creteil, France
| | - Marie-Melanie Dauplat
- 2Pathology, JPCC; ERTICa Research Team, University of Auvergne EA4677, Clermont-Ferrand, France
| | - Fabrice Kwiatkowski
- 3Clinical Research, JPCC; ERTICa Research Team, University of Auvergne EA4677, Clermont-Ferrand, France
| | | | | | - Christophe Pomel
- 6Surgical Oncology, JPCC; ERTICa Research Team, University of Auvergne EA4677, Clermont-Ferrand, France
| | | | - Nina Radosevic-Robin
- 2Pathology, JPCC; ERTICa Research Team, University of Auvergne EA4677, Clermont-Ferrand, France
| |
Collapse
|
45
|
Nabholtz J, Chalabi N, Radosevic-Robin N, Dauplat M, Mouret-Reynier M, Van Praagh I, Servent V, Jacquin JP, Benmammar K, Kullab S, Bahadoor M, Kwiatkowski F, Cayre A, Abrial C, Durando X, Bignon Y, Chollet P, Penault-Llorca F. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. Int J Cancer 2015; 138:2274-80. [DOI: 10.1002/ijc.29952] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Revised: 11/11/2015] [Accepted: 11/13/2015] [Indexed: 02/02/2023]
Affiliation(s)
- J.M. Nabholtz
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- Clinical and Translational Research Division; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- CIC 501, UMR 766; Clermont-Ferrand France
- Medical Oncology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - N. Chalabi
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- Clinical and Translational Research Division; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- CIC 501, UMR 766; Clermont-Ferrand France
| | - N. Radosevic-Robin
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- Department of Biopathology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - M.M. Dauplat
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- Department of Biopathology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - M.A. Mouret-Reynier
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- Medical Oncology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - I. Van Praagh
- Medical Oncology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - V. Servent
- Oscar Lambret Comprehensive Cancer Centre; Lille France
| | - JP Jacquin
- Lucien Neuwirth Institute; Saint-Etienne France
| | - K.E. Benmammar
- Medical Oncology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - S. Kullab
- Medical Oncology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - M.R.K. Bahadoor
- Medical Oncology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- Oncauvergne Regional Oncology Network, Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - F. Kwiatkowski
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- Clinical and Translational Research Division; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- LMB GenAuvergne Oncogenetics Department; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - A. Cayre
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- Department of Biopathology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - C. Abrial
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- Clinical and Translational Research Division; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- CIC 501, UMR 766; Clermont-Ferrand France
| | - X. Durando
- Clinical and Translational Research Division; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- CIC 501, UMR 766; Clermont-Ferrand France
- Medical Oncology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- EA 3846, University of Auvergne; Clermont-Ferrand France
| | - Y.J. Bignon
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- LMB GenAuvergne Oncogenetics Department; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| | - P. Chollet
- Clinical and Translational Research Division; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
- Inserm UMR 990; Clermont-Ferrand France
- University of Auvergne Clermont-Ferrand; Clermont-Ferrand France
| | - F. Penault-Llorca
- ERTICA EA 4677, University of Auvergne; Clermont-Ferrand France
- Department of Biopathology; Jean Perrin Comprehensive Cancer Centre; Clermont-Ferrand France
| |
Collapse
|
46
|
Bozec A, Ebran N, Radosevic-Robin N, Sudaka A, Monteverde M, Toussan N, Etienne-Grimaldi MC, Nigro CL, Merlano M, Penault-Llorca F, Milano G. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer. Laryngoscope 2015; 126:E156-63. [PMID: 26597440 DOI: 10.1002/lary.25754] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Revised: 09/09/2015] [Accepted: 09/28/2015] [Indexed: 01/10/2023]
Abstract
OBJECTIVES/HYPOTHESIS Recent preclinical and clinical studies on head and neck squamous cell carcinoma (HNSCC) revealed synergistic effects when combining anti-EGFR agents with conventional chemotherapeutic drugs. Activation of the PI3-kinase/AKT/mTOR signaling pathway has been identified as an important mechanism implicated in tumor progression and resistance to EGFR inhibitors. The aim of this study was to investigate the effects of combining the mTOR inhibitor temsirolimus (Tem) with the anti-EGFR agent cetuximab (Cet) and conventional chemotherapeutic drugs (cisplatin and fluorouracil (C/F)) on an orthotopic model of HNSCC. STUDY DESIGN Preclinical in vivo study. METHODS We evaluated the anti-tumor efficacy (measured tumor volume) of Tem, Cet, and C/F, administered alone or in combination. Investigations were performed using a human HNSCC cell line, CAL33, injected into the mouth floor of nude mice. RESULTS As compared with the control, the combination of Tem and Cet led to the highest tumor inhibition and induced almost complete tumor growth arrest (P = 0.001). Tem significantly enhanced the impact of the Cet-C/F combination on tumor growth (P < 0.001). The highest inhibitory effects of treatments on cell proliferation (Ki67 labeling), MAPK (pP42/44 labeling), and PI3K/AKT/mTOR (pS6R labeling) signaling pathways were found with the Tem-Cet association. CONCLUSION In this orthotopic HNSCC model, the combination of Tem with Cet produced synergistic effects on tumor growth. These results were corroborated by a strong inhibition of both MAPK and PI3K-mTOR signaling pathways. LEVEL OF EVIDENCE N/A.
Collapse
Affiliation(s)
- Alexandre Bozec
- Institut Universitaire de la Face et du Cou, Clermont-Ferrand, France
| | - Nathalie Ebran
- Department of Oncopharmacology, Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Department of Histopathology, Centre Jean Perrin, Clermont-Ferrand, France.,ERTICa Research Group, University of Auvergne, Clermont-Ferrand, France
| | - Anne Sudaka
- Department of Histopathology, Centre Antoine Lacassagne, Nice cedex, Clermont-Ferrand, France
| | | | - Nicolas Toussan
- Department of Histopathology, Centre Antoine Lacassagne, Nice cedex, Clermont-Ferrand, France
| | | | | | - Marco Merlano
- Department of Medical Oncology, S. Croce General Hospital, Cuneo, Italy
| | - Frédérique Penault-Llorca
- Department of Histopathology, Centre Jean Perrin, Clermont-Ferrand, France.,ERTICa Research Group, University of Auvergne, Clermont-Ferrand, France
| | - Gérard Milano
- Department of Oncopharmacology, Clermont-Ferrand, France
| |
Collapse
|
47
|
Ollier M, Radosevic-Robin N, Kwiatkowski F, Ponelle F, Viala S, Privat M, Uhrhammer N, Bernard-Gallon D, Penault-Llorca F, Bignon YJ, Bidet Y. DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition. Am J Cancer Res 2015; 5:2113-2126. [PMID: 26328243 PMCID: PMC4548324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 06/11/2015] [Indexed: 06/04/2023] Open
Abstract
Among breast cancers, 10 to 15% of cases would be due to hereditary risk. In these familial cases, mutations in BRCA1 and BRCA2 are found in only 15% to 20%, meaning that new susceptibility genes remain to be found. Triple-negative breast cancers represent 15% of all breast cancers, and are generally aggressive tumours without targeted therapies available. Our hypothesis is that some patients with triple negative breast cancer could share a genetic susceptibility different from other types of breast cancers. We screened 36 candidate genes, using pyrosequencing, in all the 50 triple negative breast cancer patients with familial history of cancer but no BRCA1 or BRCA2 mutation of a population of 3000 families who had consulted for a familial breast cancer between 2005 and 2013. Any mutations were also sequenced in available relatives of cases. Protein expression and loss of heterozygosity were explored in tumours. Seven deleterious mutations in 6 different genes (RAD51D, MRE11A, CHEK2, MLH1, MSH6, PALB2) were observed in one patient each, except the RAD51D mutation found in two cases. Loss of heterozygosity in the tumour was found for 2 of the 7 mutations. Protein expression was absent in tumour tissue for 5 mutations. Taking into consideration a specific subtype of tumour has revealed susceptibility genes, most of them in the homologous recombination DNA repair pathway. This may provide new possibilities for targeted therapies, along with better screening and care of patients.
Collapse
Affiliation(s)
- Marie Ollier
- Department of Molecular Oncology, Centre Jean PerrinClermont-Ferrand 63000, France
- Université d’AuvergneEA 4677, ERTICa, BP 10448, Clermont-Ferrand 63000, France
| | - Nina Radosevic-Robin
- Department of Anatomopathology, Centre Jean PerrinClermont-Ferrand 63000, France
- Université d’AuvergneEA 4677, ERTICa, BP 10448, Clermont-Ferrand 63000, France
| | - Fabrice Kwiatkowski
- Department of Molecular Oncology, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Flora Ponelle
- Department of Molecular Oncology, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Sandrine Viala
- Department of Molecular Oncology, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Maud Privat
- Department of Molecular Oncology, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Nancy Uhrhammer
- Department of Molecular Oncology, Centre Jean PerrinClermont-Ferrand 63000, France
| | | | - Frédérique Penault-Llorca
- Department of Anatomopathology, Centre Jean PerrinClermont-Ferrand 63000, France
- Université d’AuvergneEA 4677, ERTICa, BP 10448, Clermont-Ferrand 63000, France
| | - Yves-Jean Bignon
- Department of Molecular Oncology, Centre Jean PerrinClermont-Ferrand 63000, France
- Université d’AuvergneEA 4677, ERTICa, BP 10448, Clermont-Ferrand 63000, France
| | - Yannick Bidet
- Department of Molecular Oncology, Centre Jean PerrinClermont-Ferrand 63000, France
- Université d’AuvergneEA 4677, ERTICa, BP 10448, Clermont-Ferrand 63000, France
| |
Collapse
|
48
|
Abstract
The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification.
Collapse
Affiliation(s)
- Paolo Nuciforo
- Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain.
- Universitat Autònoma de Barcelona, Barcelona, 08035, Spain.
| | - Nina Radosevic-Robin
- ERTICa Research Group, University of Auvergne EA4677, 63000, Clermont-Ferrand, France.
- Biopathology, Jean Perrin Comprehensive Cancer Center, 58 rue Montalembert, 63011, Clermont-Ferrand, France.
| | - Tony Ng
- Richard Dimbleby Department of Cancer Research, Randall Division of Cell and Molecular Biophysics and Division of Cancer Studies, King's College London, London, SE1 1UL, UK.
- UCL Cancer Institute, Paul O'Gorman Building, University College London, London, WC1E 6DD, UK.
- Breakthrough Breast Cancer Research Unit, Department of Research Oncology, Guy's Hospital King's College London School of Medicine, London, SE1 9RT, UK.
| | - Maurizio Scaltriti
- Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY, 10065, USA.
| |
Collapse
|
49
|
Wang-Lopez Q, Chalabi N, Abrial C, Radosevic-Robin N, Durando X, Mouret-Reynier MA, Benmammar KE, Kullab S, Bahadoor M, Chollet P, Penault-Llorca F, Nabholtz JM. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Crit Rev Oncol Hematol 2015; 95:88-104. [PMID: 25900915 DOI: 10.1016/j.critrevonc.2015.02.011] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2014] [Revised: 01/22/2015] [Accepted: 02/09/2015] [Indexed: 10/23/2022] Open
Abstract
Breast cancer is heterogeneous in clinical, morphological, immunohistochemical and biological features, as reflected by several different prognostic subgroups. Neoadjuvant approaches are currently used for the "in vivo" efficacy assessment of treatments. Pathological complete response (pCR) has been reported as a reliable predictive factor of survival in that setting. However, pCR remains a subject of controversy in terms of definition and its evaluation methods. In addition, its predictive value for patient outcome in various breast cancer biological subtypes has been under debate. In this review, we will present the existing definitions of pCR, the impact of its evaluation methods on its rate and the assessment of its predictive value for patient outcome in the molecular subtypes of breast cancer (luminal A and B, Triple Negative and HER2-positive).
Collapse
Affiliation(s)
- Qian Wang-Lopez
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France; Inserm UMR 990, 63000 Clermont-Ferrand, France
| | - Nassera Chalabi
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France; ERTICA EA 4677, University of Auvergne, 63000 Clermont-Ferrand, France; CIC 501, UMR 766, 63003 Clermont-Ferrand, France
| | - Catherine Abrial
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France; ERTICA EA 4677, University of Auvergne, 63000 Clermont-Ferrand, France; CIC 501, UMR 766, 63003 Clermont-Ferrand, France
| | - Nina Radosevic-Robin
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France; ERTICA EA 4677, University of Auvergne, 63000 Clermont-Ferrand, France
| | - Xavier Durando
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France; CIC 501, UMR 766, 63003 Clermont-Ferrand, France; CREAT EA 7283, University of Auvergne, 63000 Clermont-Ferrand, France
| | - Marie-Ange Mouret-Reynier
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France; ERTICA EA 4677, University of Auvergne, 63000 Clermont-Ferrand, France
| | | | - Sharif Kullab
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France
| | - Mohun Bahadoor
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France
| | - Philippe Chollet
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France; Inserm UMR 990, 63000 Clermont-Ferrand, France
| | - Frédérique Penault-Llorca
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France; ERTICA EA 4677, University of Auvergne, 63000 Clermont-Ferrand, France.
| | - Jean-Marc Nabholtz
- Jean Perrin Comprehensive Cancer Centre, 63011 Clermont-Ferrand, France; ERTICA EA 4677, University of Auvergne, 63000 Clermont-Ferrand, France
| |
Collapse
|
50
|
Gay-bellile M, Radosevic-Robin N, Eymard-Pierre E, Kwiatkowski F, Dauplat MM, Privat M, Abrial C, Combes P, Soler G, Bignon YJ, Nabholtz JM, Vago P, Penault-Llorca F, Tchirkov A. Abstract 550: Genomic instability and telomere characteristics as predictive biomarkers of therapeutic response in triple-negative breast cancer. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Triple negative breast cancers (TNBC) represent about 15 % of invasive breast carcinomas. These tumors are identified in clinical practice according to their “triple negative” immunophenotype (estrogen receptor, progesterone receptor and HER2 negative). TNBC show aggressive behavior and an unusual sarcoma-like pattern of metastasis. Identification of predictive biomarkers is critical to optimal therapeutic management of these tumors. TNBC are characterized by increased genomic instability. These tumors present complex pattern of numerous low-amplitude genomic gains and losses as well as shorter telomeres.
Aim. Identification of predictive biomarkers of response to neoadjuvant chemotherapy in TNBC by evaluating telomeric parameters and genomic instability.
Methods. We studied 38 TNBC patients treated with neoadjuvant chemotherapy according to the TVA protocol (FEC 100, docetaxel, panitumumab). DNA and RNA were extracted from snap-frozen tumor samples obtained before neoadjuvant therapy. The pathological response to treatment was evaluated according to Chevallier's and Sataloff's classifications and correlated with aCGH profiles (8x60K, Agilent) and telomere characteristics, including telomere length (qPCR) and expression (qRT-PCR) of telomerase (hTERT) and shelterin complex genes (TRF1, TRF2, POT1, TPP1, RAP1 and TIN2).
Results. Telomere shortening and high hTERT expression were found in more aggressive tumors according to TNM classification (P< 0.04), and hTERT expression was also highly correlated with an increased tumor size (P= 0.0058). Short telomeres were strongly associated with incomplete histological response to neoadjuvant therapy according to Chevallier's (P= 0.0004) and Sataloff's classifications, (P= 0.0007). hTERT expression was significantly increased in cases with incomplete response (P< 0.04). Among shelterin complex genes, TRF2 and TPP1 overexpression was found in more aggressive TNBC (according to TNM classification and SBR grading, P< 0.05), but there was no correlation with pathological response. aCGH data indicated that genomic instability in non-responders was mainly represented by genomic gains. In particular, cases with incomplete therapeutic responses showed significantly larger size of gains than cases with complete responses. (P= 0.0089). Short telomeres were also associated with larger gains of genomic material (P= 0.0067). Of note, telomere shortening has been previously described as one of the mechanisms of genomic gains and amplifications.
Conclusions. Telomere shortening and hTERT overexpression were observed in resistant TNBC. Genomic profile of non-responding tumors was characterized by larger genomic gains. Telomere length, hTERT expression and genomic instability profiles may represent predictive biomarkers of response to neoadjuvant chemotherapy in TNBC.
Citation Format: Mathilde Gay-bellile, Nina Radosevic-Robin, Eleonore Eymard-Pierre, Fabrice Kwiatkowski, Marie-Mélanie Dauplat, Maud Privat, Catherine Abrial, Patricia Combes, Gwendoline Soler, Yves-Jean Bignon, Jean-Marc Nabholtz, Philippe Vago, Frédérique Penault-Llorca, Andreï Tchirkov. Genomic instability and telomere characteristics as predictive biomarkers of therapeutic response in triple-negative breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 550. doi:10.1158/1538-7445.AM2014-550
Collapse
Affiliation(s)
| | | | | | | | | | - Maud Privat
- 2ERTICa 4677 and Centre Jean Perrin, Clermont-Ferrand, France
| | | | | | | | | | | | - Philippe Vago
- 1ERTICa 4677 and CHU Estaing, Clermont-Ferrand, France
| | | | | |
Collapse
|